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Liver cancer has the second highest worldwide
cancer mortality rate and has limited therapeutic op-
tions. We analyzed 363 hepatocellular carcinoma
(HCC) cases by whole-exome sequencing and DNA
copy number analyses, and we analyzed 196 HCC
cases by DNA methylation, RNA, miRNA, and prote-
omic expression also. DNA sequencing andmutation
analysis identified significantly mutated genes,
including LZTR1, EEF1A1, SF3B1, and SMARCA4.
Significant alterations bymutation or downregulation
by hypermethylation in genes likely to result in HCC
metabolic reprogramming (ALB, APOB, and CPS1)
were observed. Integrativemolecular HCC subtyping
incorporating unsupervised clustering of five data
platforms identified three subtypes, one of which
was associated with poorer prognosis in three HCC
cohorts. Integrated analyses enabled development
of a p53 target gene expression signature correlating
with poor survival. Potential therapeutic targets
for which inhibitors exist include WNT signaling,
MDM4, MET, VEGFA, MCL1, IDH1, TERT, and im-
mune checkpoint proteins CTLA-4, PD-1, and PD-L1.
INTRODUCTION
Liver cancer is the second most common cause of death from
cancer worldwide, with 700,000 annual deaths recorded globally
in recent years (Ferlay et al., 2015). Hepatocellular carcinoma
(HCC), the predominant form of liver cancer, has several known
risk factors, including chronic hepatitis B virus (HBV) and hepa-
titis C virus (HCV) infections, alcohol abuse, autoimmune hepati-
tis, diabetesmellitus, obesity, and several metabolic diseases. In
developed nations, there has been a rise in HCC incidence partly
attributed to HCV, obesity, and diabetes (Yang and Roberts,
2010). The liver injury induced by these risk factors produces a
progressive inflammatorymilieu that results in a cycle of necrosis
and regeneration and the development of chromosomal insta-
bility (Karagozian et al., 2014). Genetic and epigenetic alterations
that progressively accumulate in a background of increased
reactive oxygen species, inflammatory cytokines, and fibrosis
likely lead to the initiation of HCC (Dhanasekaran et al., 2016).
Initiation and progression of HCC is considered a multi-step
process, but the precise molecular events that underlie HCCformation remain only partially understood (Zucman-Rossi
et al., 2015).
Recent studies have explored HCC genomic alterations and
have identified frequently mutated genes, including TERT pro-
moter, TP53, and CTNNB1 (b-catenin) (Schulze et al., 2015;
Totoki et al., 2014). Despite many potential therapeutic targets,
sorafenib and regorafenib, related multikinase inhibitors, are
currently the only drug approved for advanced HCC manage-
ment (Llovet et al., 2008). More than ten drugs have failed to
meet clinical end points in phase III trials, indicating a need for
new drug discovery for HCC (Llovet and Hernandez-Gea, 2014).
As part of The Cancer Genome Atlas (TCGA) network, we have
performed the first large-scale multi-platform analysis of HCC,
including evaluation of somatic mutations and DNA copy number
in 363 patients and examination of DNA methylation, mRNA
expression, microRNA (miRNA) expression, and protein expres-
sion in 196 patients to understand the molecular landscape of
HCCs (Tables S1A–S1C). Tissue and tumor specimens were ob-
tained from patients with appropriate consent from institutional
review boards under the guidelines of The Cancer Genome Atlas
Research Network.’ The integrated analyses of multiple data
platforms in conjunction with clinical data (Tables S1A and S1B)
has facilitated biological insights, identification of therapeutic tar-
gets, and the characterization of robust subclasses with prog-
nostic implications that may influence HCC clinical management.
RESULTS
Somatic Mutations
Whole-exome sequencing was performed on 363 HCC cases for
a mean coverage of 95% of targeted bases with a minimum of
20-fold coverage. In total, 12,136 genes had non-silent muta-
tions, and 26 genes were determined to be significantly mutated
genes (SMGs) by theMutSigCV algorithm (Lawrence et al., 2014)
(Figure 1, Tables S2A and S2B, STAR Methods). Of these 26
genes, 18 were reported as SMGs in at least one previous
HCC genome sequencing study (Table S2B). These included
the tumor suppressor genes TP53 (31%), AXIN1 (8%), and
RB1 (4%) that were inactivated by mutation, the WNT pathway
oncogene CTNNB1 (27%), and the chromatin remodeling genes
ARID1A (7%), ARID2 (5%), and BAP1 (5%) (Figure 1, Tables S2A
and S2B).NFE2L2 and its interactor KEAP1, important in cellular
anti-oxidant defenses, were significantly mutated in 3% and 5%
of HCC, respectively. Albumin (ALB) and APOB mutations were
observed in 13% and 10% of tumors, consistent with previous
HCC sequencing studies (Figure 1, Table S2B) (Fujimoto et al.,
2016; Schulze et al., 2015). ALB and APOB RNA expression
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Figure 1. The Genomic Landscape of Liver Hepatocellular Carcinoma and Mutational Signatures
Top panel shows individual tumor mutation rates while the middle panel details ethnicity, tumor grade, age, gender, hepatitis C virus (HCV) and hepatitis B virus
(HBV) infection status, and cirrhosis for 363 HCC patients.
Bottom panel shows genes with statistically significant levels of mutation (MutSig suite, FDR, < 0.1), andmutation types are indicated in the legend at the bottom.
The bottom six rows display significant DNA copy number alterations in likely cancer driver genes.
See also Figures S1 and S2.were decreased in HCC relative to normal tissues. HCC stratified 
by low ALB and APOB expression were associated by gene set 
enrichment analysis (GSEA) with increased cell cycle progres-
sion, ribosome biogenesis and nucleotide synthesis, and 
reduced oxidative phosphorylation (data not shown). Because 
ALB expression accounts for 20% of cellular mRNA (Uhle´ n 
et al., 2015) and APOB consumes large amounts of cellular 
energy by facilitating VLDL secretion (Egusa et al., 1985), there 
may be selection for ALB or APOB inactivating mutations to 
divert energy into cancer-relevant metabolic pathways (Fernan-
dez-Banet et al., 2014).
Among the 26 MutSigCV-identified SMGs were eight genes 
not previously considered candidate HCC drivers (Table S2B). 
LZTR1, encoding an adaptor of CUL3-containing E3 ligase 
complexes, was mutated in 10 of 377 HCC (3%). Eight LZTR1 
mutations were inactivating splice-site mutations at codon 
217, a mutation observed in adrenocortical and pancreatic can-
cers (Witkiewicz et al., 2015). LZTR1 germline mutations have 
been associated with inherited segmental schwannomatosis, 
and somatic LTZR1 mutations are identified as driver mutations 
in glioblastoma (Frattini et al., 2013; Piotrowski et al., 2014). The 
translation elongation factor gene EEF1A1 was significantly 
mutated in ten tumors and five tumors contained S432I/S muta-
tions, a codon mutation observed in HCC and other cancers (Ahn 
et al., 2014). Other genes identified as significantly mutated 
by MutSigCV included AZIN1, RP1L1, GPATCH4, CREB3L3,AHCTF1, and HIST1H1C. None of these six genes have been re-
ported as drivers in HCC or other cancers.
In addition to algorithmically curated SMGs, we manually
curated two genes with MutSigCV q values close to 0.1 as likely
driver genes due to recurrent mutations. SF3B1, a splicing factor
gene, was mutated in ten patients, with mutations in codons
N626 and K666 occurring twice each in our HCC tumor set and
11and21 times, respectively, acrossother tumor studies (Cerami
et al., 2012).SF3B1mutations have been reported as likely driver
mutations in hematopoietic malignancies (Bonnal et al., 2012).
SMARCA4, encoding a chromatin modifier of the SWI/SNF fam-
ily, was mutated in 11 HCC patient tumors. Mutations at codons
1,160 and 1,192 occurred twice andwere observed at this codon
in 6 and 14 other non-HCC tumors, respectively (Cerami et al.,
2012).Mutations inSMARCA4 have been observed in some can-
cer types, including 4 of 36 HCC cases (Endo et al., 2013).
TERT promoter mutations were the most common somatic
mutation, found in 87 of 196 (44%) HCCs analyzed in the
TERT promoter region (Figure S1A, Table S3). Two indepen-
dent TERT promoter mutations—chr5, 1,295,228 G>A (C228T)
and 1,295,250 G>A (C250T)—were found, consistent with
activating mutations previously reported (Horn et al., 2013).
Further analysis revealed a germline TERT promoter muta-
tion (C228T) in the blood and tumor of an HBV-positive 29-year-
old Asian male with no recorded family history of HCC. Germline
TERT mutations (1,295,161 T>G at the transcription start site)
were associated with familial melanoma (Horn et al., 2013), but a
germline mutation at position C228T has not been reported.
Patients with a TERT promoter mutation were older
(p = 0.0006), predominantly male (p = 0.006), more likely to be
HCV positive (p = 0.04), and less likely to be HBV positive
(p = 0.02) thanpatientswithout themutation.Molecular correlates
of TERT promotermutation included a strong co-occurrencewith
CDKN2A silencingbypromoter hypermethylation (p = 8.13 105)
(Figure S1A). CDKN2A encodes the tumor suppressor p16INK4A,
and downregulation of p16INK4A expression in conjunction with
enhanced TERT expression has been shown to be essential for
epithelial cell immortalization, a cancer hallmark (Kiyono et al.,
1998). TERTRNAwas significantly upregulated in theHCCcohort
overall (p < 0.001), but TERT promoter mutation did not signifi-
cantly correlate with increased TERT RNA expression.
Mutational Signatures
We performed mutational signature analysis on the core set of
196 HCC applying a Bayesian variant of the non-negative matrix
factorization (NMF) algorithm (Tan and Fe´votte, 2013) to muta-
tion counts of single-nucleotide variants (SNVs) stratified by
96-trinucleotide contexts. This analysis identified three indepen-
dent mutational signatures (A, B, and C, STAR Methods), of
which two correspond to reported mutation signatures (Alexan-
drov et al., 2013) (see also http://cancer.sanger.ac.uk/cosmic/
signatures). To identify additional samples with a significant
enrichment of each mutational process, we performed a hierar-
chical clustering of normalized signature activity (Figure S1B).
Nine samples significantly associated with the plant-derived
carcinogen aristolochic acid (AA) signature had a predominance
of A:T-to-T:A transversions at [CjT]AG tri-nucleotide motifs, and
these samples had a significant enrichment of splice-site
mutations (p = 106 by Wilcoxon rank-sum test) due to overlap
of the motif with the canonical splice-acceptor site. Seven sam-
ples were significantly correlated with mutational signature B
(sig B), associated with Aflatoxin B1 exposure, and character-
ized by an excess of G:C-to-T:A transversions. Aflatoxin B1
exposure is a risk factor for HCC, associated with hotspot muta-
tion R249S. Recurrent TP53-R249S mutant samples had signif-
icant enrichment of AFB1 signature activity in comparison to
other TP53 mutants (p = 0.005 by Wilcoxon rank-sum) or WT
samples (p = 0.0001) (Figure S1C). HBV-positive samples had
much higher AFB1 activity than HBV-negative HCC (p = 0.005
by Wilcoxon rank-sum), indicating a likely synergistic interaction
between Aflatoxin B1 exposure and HBV.
Copy Number Changes
Somatic copy number alterations (SCNAs) were determined by
profiling HCC on Affymetrix SNP 6.0 arrays and analysis by
GISTIC 2.0. Overall patterns of broad and focal alterations
across the entire cohort were similar to earlier reports (Guichard
et al., 2012; Totoki et al., 2014) (Figure S2A). Most frequent chro-
mosomal arm alterations included copy number gains in 1q and
8q and copy number losses in 8p and 17p (Figures S2A and
S2B). GISTIC 2.0 analysis of all tumors identified 28 significantly
reoccurring focal amplifications, including those containing well-
characterized driver oncogenes such as CCND1 and FGF19
(11q13.3), MYC (8q24.21), MET (7q31.2), VEGFA (6p21.1), andMCL1 (1q21.3). Moreover, TERT (5p15.33) was amplified in
10% of HCC cases. Among 36 deletion events, 13q14.2 (RB1)
and 9p21.3 (CDKN2A) were prominent (Figure S2B). Also seen
was a 1p36.23 focal deletion peak that includes the tumor sup-
pressor ERRFI1, recently described in gliomas and HCC (Park
et al., 2015). We noted a 17p11.2 focal deletion that contained
the tumor suppressor NCOR1, which functions as a suppressor
of beta catenin expression (Song and Gelmann, 2008).
Methylation Profiling
Comparison of genome-scale DNA methylation profiles in
normal tissue and HCC revealed significant amounts of both
hypo- and hypermethylation in the tumors. Unsupervised clus-
tering of HCC using CpG sites that showed cancer-specific
DNA hypermethylation identified four hypermethylation clusters
(Figure 2A). Two clusters (3 and 4) exhibited elevated hyperme-
thylation. Cluster 3 in particular contained all of the tumors with
IDH1 and/or IDH2 (IDH1/2) mutations and exhibited a distinct
DNA hypermethylation profile (Figure 2A), consistent with previ-
ous data that IDH1/2mutations are gain-of-function lesions that
increase levels of cellular D-2-hydroxyglutarate that regulate
genomic methylation rates (Lu et al., 2012). Cluster 4 HCC
cases were disproportionately enriched for CDKN2A epigenetic
silencing, TERT promoter mutations, and CTNNB1 mutations
(Figure 2A). Asian ethnicity and HBV infection were significantly
associated with cluster 1, whereas HCV infection was signifi-
cantly associated with cluster 4.
Two approaches (see STAR Methods) were used to identify
those genes with high levels of tumor-specific hypermethylation
in conjunction with reduced RNA expression (Table S4A). Seven
representative genes frequently hypermethylated in our HCC
sample set are shown in Figures 2B–2H. These genes displayed
significantly reduced RNA expression correlated with high-
frequency promoter hypermethylation. CDKN2A epigenetic
silencing was found in 53% (102/191) of samples, whereas
CDKN2A mutations were observed in 4% of HCC patients, indi-
cating that DNA methylation is the predominant mechanism for
CDKN2A inactivation (Figure 2B, Table S4A) in HCC.Other highly
hypermethylated and downregulated genes included HHIP, a
suppressor of hedgehog signaling, a pathway important in hep-
atocarcinogenesis (Zheng et al., 2013) (Figure 2C, Table S4A),
prostaglandin reductase 1 (PTGR1), shown to inhibit lung cancer
growth (Zhao et al., 2010) (Figure 2D, Table S4A), and
TMEM106A, encoding a pro-apoptotic protein downregulated
in gastric cancer (Xu et al., 2014) (Figure 2E, Table S4A). Mem-
bers of the metallothionein family, MT1M and MT1E, have
been implicated as tumor suppressors in HCC and other cancers
(Mao et al., 2012) (Figures 2F and 2G, Table S4A).
Hypermethylation-mediated downregulation of CPS1 (carba-
moyl phosphate synthase I), a liver-specific rate-limiting enzyme
of the urea cycle reported as a HCC-hypermethylated gene (Liu
et al., 2011), may favor glutamine usage in HCC by CAD (carba-
moyl phosphate synthase II), which initiates the de novo pyrimi-
dine synthesis pathway, thus favoring cell division (Figure 2H,
Table S4A). Consistent with this hypothesis, mean CAD RNA
levels were 2.8-fold increased in HCC relative to normal liver tis-
sues (p = 6.7 3 1034), whereas mean CPS1 RNA levels were
2.1-fold reduced in HCC compared to normal liver tissue.
Figure 2. Liver Cancers Show Distinct Gene Hypermethylation Patterns
(A) Unsupervised clustering analysis of gene hypermethylation in HCC tumor relative to normal tissue reveals four distinct subgroups. Roughly 15,000 CpG sites
showing significant hypermethylation in 196 HCC patients were analyzed and are shown in heatmap format with normal tissues and tumors organized in columns
according to cluster designation. Intensity of methylation for each CpG site is indicated by row. Above the heatmap the four distinct hypermethylation clusters are
shown, and below are bars indicating the distribution of clinical and molecular attributes of the individual tumors by cluster. To the right, p values indicate
significant non-random distributions for each attribute.
See also Tables S4A and S4B.
(legend continued on next page)
Of the 298 genes exhibiting significant HCC-specific hyperme-
thylation, 81 have been reported to be hypermethylated and
another 28 have been reported to be downregulated (methyl-
ation status unknown) in HCC or other cancers relative to normal
tissues (Table S4A). GSEA of these 298 hypermethylated genes
showed enrichment for pathways related to differentiation, stem
cell maintenance, and targets of the Polycomb repressive com-
plex, a phenomenon previously reported (Widschwendter et al.,
2007) (Table S4B).
HBV and HCV Infection
Chronic HBV and HCV infection are major viral risk factors for
HCC. In the core TCGA dataset, 44 of 196 (22.4%) patients dis-
played clinical and molecular evidence of HBV infection. HBV
infection was significantly associated with Asian ethnicity,
younger age at initial diagnosis, and male gender (Table S5A).
HBV+ HCC patients were significantly more likely to be mutated
in TP53 and significantly less likely to harbor TERT promoter mu-
tations than HBV HCC patients.
Most (37/44, 84%) HBV-infected HCC patients exhibited evi-
dence of HBV DNA integration into the host genome by analysis
of RNA sequence reads for HBV-chromosomal gene fusion tran-
scripts. Such integrated viral genomes raise the possibility of cis-
activation or inactivation of cancer regulatory genes, believed to
be an occasional source of driver mutations in HCC. RNA fusion-
based HBV integration sites identified by two methods are
shown in Table S5B. Roughly 50% of HBV integration sites
were within genes, though only two genes had recurrent muta-
tions: MLL4, a histone methyltransferase that regulates prolifer-
ation and is reported as a frequent HBV integration site (Saigo
et al., 2008), and TERT. The five tumors with MLL4 insertions
and one of the two TERT insertions displayed the highest levels
of MLL4 and TERT RNA expression among all HCC, suggesting
an HBV cis-activating event (Table S5C). Among the non-recur-
ring HBV insertional events associated with very high levels of
RNA transcription, potential driver events were observed. These
include known oncogenes CCND1, CCNE1, and GLI2 (a sonic
hedgehog transcription factor). Thus, the effect of HBV on tran-
scriptional levels of key oncogenes demonstrated potential
driver events affecting a number of patients.
In our HCC samples, 35 of 196 (17.9%) patients exhibited
serological and/or molecular markers of HCV infection, by pres-
ence of HCV antibody or HCVRNAas determined by commercial
HCV RNA testing or by sequence analysis. HCV infection was
significantly higher in white and black patients than Asian pa-
tients and in patients with cirrhosis (Figure 1). HCV+ tumors dis-
played significantly increased frequency of CDKN2A promoter
silencing (p = 0.0061) and TERT promoter mutation (p = 0.014).
Multi-platform Integrative Molecular Subtyping
Unsupervised clustering of data from five platforms (DNA copy
number, DNA methylation, mRNA expression, miRNA expres-
sion and RPPA) resulted in a collection of discordant subgroup-(B–H) Scatterplots of representative CpG sites in gene promoters shown to be freq
against relative promoter site hypermethylation (x axis). Gray dots are results fro
results from tumors with mutations in the gene. (B) CDKN2A (cg13601799). (C)
(F) MT1M (cg15134649). (G) MT1E (cg02512505). (H) CPS1 (cg21967368).ings specific to each data platform. To reconcile these disparate
data types, we used a joint multivariate regression approach (see
STAR Methods) to simultaneously cluster data from the five
platforms. This comprehensive approach resolved three major
subtypes (Figure 3A, Figures S3A and S3B). The majority of indi-
vidual platform cluster solutions concentrated preferentially in
one of the three integrated iCluster solutions with p < 0.0001
(Figures S3A and S3C), lending confidence that the aggregate
solution captured the main features of each platform. The asso-
ciation of the three iClusters with demographic, pathologic, and
molecular features of the HCC patients strengthened the clinical
relevance of the subtypes defined by the iCluster procedure.
The first integrated cluster, iClust1 (n = 65), was characterized
by clinical associations with younger age, Asian ethnicity, female
gender, and normal body weight (Table S6, Figure S3B). These
tumors exhibited features such as higher tumor grade and pres-
ence of macrovascular invasion and had the lowest fraction
of differentiated samples by Hoshida classification (Hoshida
et al., 2009) (Table S6, Figure 3B, Figure S3B). Molecular corre-
lations with iClust1 included a low frequency of CDKN2A
silencing (32%) as compared to iClust2 and iClust3 (69% and
63%, respectively), a low frequency of CTNNB1 mutation (12%
in iClust1 versus 38% and 43% in iClust2 and iClust3, respec-
tively), and a low frequency of TERT promoter mutation and
low TERT expression (Figure 3A, Table S6). iClust1 tumors ex-
hibited specific changes in miRNA expression, including high
expression ofmiR-181a (a lipidmetabolism regulator) and epige-
netic silencing of miR-122 (Figure S3D). This subclass was asso-
ciated with overexpression of proliferation marker genes such as
MYBL2, PLK1, and MKI67 (Figure S3D).
In contrast, iClust2 (n = 55) and iClust3 (n = 63) exhibited a high
frequency of CDKN2A silencing by DNA hypermethylation, a
high frequency of TERT promoter mutations and CTNNB1muta-
tions, and enrichment for HNF1A mutation. Correlation with
clinical variables revealed association of iClust2 with low-grade
tumors (p = 0.0006) and less microvascular invasion (p = 0.01)
(Table S6, Figure S3B). iClust3 was characterized by a higher
degree of chromosomal instability with distinct 17p loss, high
frequency of TP53 mutation, and hypomethylation of multiple
CpG sites.
To compare the iCluster classification to previous molecular
subclasses, we assigned each of our patients to one of the three
mRNA expression-based subclasses fromHoshida and collabo-
rators (Hoshida et al., 2009) by using prediction signatures devel-
oped from their expression data. We found correspondence
between the iClusters and Hoshida subclasses (C1–C3) (Table
S6). iClust1 consisted predominantly of Hoshida C2 patients,
whereas iClust3 consisted predominantly of HoshidaC3 patients
(Figure 3B).
We further tested the clinical relevance of the iCluster group-
ings by constructing a subclass prediction model based on the
200 most variably expressed genes compared across the three
iClusters (STARMethods). We then tested the predictor on threeuently hypermethylated in HCC, where gene RNA expression (y axis) is plotted
m tumor samples, blue dots are results from normal tissues, and red dots are
HHIP (cg23109129). (D) PTGR1 (cg13831329). (E) TMEM106A (cg21211480).
A B
C
Figure 3. Multi-platform Clustering Analysis Identified Three Integrated Molecular Subtypes of Liver Cancer
(A) Heatmaps organized by iCluster groupings for DNA copy number, DNA methylation status, mRNA expression, and miRNA expression and correlated with
selected molecular features (top tracks). Tumors are in columns, grouped by the iCluster membership.
(B) Relative proportions in each iCluster of Hoshida et al. (2009) subtypes defined by RNA expression profiling of a separate HCC cohort.
(C) Patient survival outcome fitting three external clinically annotated HCC patient cohort sets of RNA expresson data to the TCGA iClusters (NCI, Lee et al., 2006;
Fudan, Roessler et al., 2010; MDACC, Sohn et al., 2016).
See also Figure S3.published datasets of three external clinically annotated HCC 
patient cohorts, with long term follow-up (Lee et al., 2006; 
Roessler et al., 2010; Sohn et al., 2016). Among all three external 
cohorts, iClust1 had significantly worse prognosis than iClust2 
and iClust3 (Figure 3C). There was no difference in overall 
survival between the three clusters in the TCGA cohort 
(p = 0.561), possibly due to the relatively short follow-up times 
in this dataset (median follow-up, 18 months) (Table S1A). None-
theless, robust replication of poor survival in iClust1 in three in-
dependent datasets suggests it is a reliable clinical predictor of 
outcome.
IDH1/2 Mutations and miR-122 Expression
Analysis of the mutation data revealed two mutations in IDH1 
(R132C and R132G) and two mutations in IDH2 (R172K and 
R172S), in four different tumors. These specific IDH1/2 muta-
tions, seen in multiple human cancers, result in a neomorphic 
isocitrate dehydrogenase that produces an oncometabolite 
believed to alter cellular epigenetic programs and block normal 
differentiation (Lu et al., 2012). IDH1/2 mutations are more 
frequent in intrahepatic cholangiocarcinomas (CCA) than in 
HCC, hence the possibility that these tumors actually repre-
sented mixed HCC-CCA was considered. We carefully re-
viewed the histopathology of these tumors and all of themexhibited features of HCC and not of mixed tumor or
cholangiocarcinoma.
When the Bayesian compound covariate predictor (BCCP)
algorithm (Radmacher et al., 2002) was applied to the mRNA
expression data, 11 samples with gene expression patterns
similar to the IDH1/2-mutated samples were identified; however,
these samples did not have IDH1/2mutations (Figure 4A). When
compared with other molecular subtypes of HCC, the IDH
mutant and IDH-like samples exhibited the highest similarity to
an hepatic stem cell-like subtype (Lee et al., 2006). These sam-
ples were all classified with the poor prognosis iClust1 subclass
and exhibited similarity to non-differentiated RNA clustering
phenotypes (Hoshida C2) (Hoshida et al., 2009), cholangiocarci-
noma-like HCC (Woo et al., 2010), silencing of the Hippo
pathway (Sohn et al., 2016), and had high risk scores based on
a gene expression signature of 65 genes (Borger et al., 2012)
(Figure 4A), suggesting that HCC with the IDH-like gene expres-
sion signature represents a poor prognostic subtype of HCC.
The IDH-like gene expression signature was present in similar
proportions in the follow-up TCGA extended HCC cohort, and
in four other published HCC cohorts with extended follow-up
data (Figure 4B). It was associated with significantly worse sur-
vival (Figure 4C) in the aforementioned three external cohorts
with survival data (see above and also Figure 3C).
Figure 4. HCC Patients with IDH1/2 Mutations and with IDH-Like Gene Expression Share miRNA and RNA Expression Profiles and Worse
Clinical Outcomes
(A) Integrated analysis of IDH1/2mutations (bottom), mRNA andmiRNA expression data (middle), and iCluster andmolecular subtypes of HCC (top). HS, hepatic
stem cell subtype; CCL, cholangiocarcinoma-like subtype; Hippo, Hippo pathway subtype; RS65, 65-gene risk score subtype; NCIP, National Cancer Institute
proliferation subtype; SNUR, Seoul National University recurrence subtype; HB16, 16-gene hepatoblastoma subtype; Hoshida, HCC RNA expression subtype
profiling category.
(B) Comparison of mRNA expression profiles of two TCGA HCC cohorts and four other HCC cohorts showing subsets of tumors with IDH-like gene expression.
(C) Clinical significance of IDH-like subtype in HCC. Patients in three external cohorts were stratified according to IDH-like gene expression signature.
See also Figure S4.Genes and microRNAs that were differentially expressed in
IDHmutant and IDH-like tumorswere also identified (Figure S4A).
Intriguingly, miR-122, which is liver-specific and the most abun-
dant miRNA in liver (Figure S4B), was significantly downregu-
lated in some of the IDHmutant and IDH-like tumors by promoter
DNA hypermethylation (Figure S4C). miR-122 dysregulation has
been observed in HCC studies and has been associated with
poor survival (Coulouarn et al., 2009). miR-122 regulates the
expression of multiple genes, including PKM2 (Figure S4D),
and is implicated in metabolism as well as HCC progression
(Liu et al., 2014). The four IDH-mutant samples had a distinct
DNA hypermethylation profile, as seen in other cancer types,
while the IDH-like samples lacked the characteristic DNA hyper-
methylation profile.
P53 Signature
Mutations involving TP53 were found in 31% of patients. We
used an alternate method to determine p53 functional status
by assessment of p53 transcriptional target expression (p53
signature). The degree of p53 target gene upregulation is used
as a surrogate for p53 functionality (see TP53 Signature in
STAR Methods). Tumors were stratified based on p53 target
gene expression (Figure 5A). While only one HCC with high
p53 target expression had a TP53 mutation, 11 out of 48 (23%)
samples in the low p53 expression quartile were TP53 wild-
type. Thus, many HCCs without TP53 mutations appear tohave inactive p53, consistent with the existence of non-muta-
tional p53 inactivatingmechanisms (Soussi, 2014).We examined
specific inhibitors of p53 function and found that MDM4, a p53
inhibitory protein, was significantly increased in copy number
and expression in low signature WT TP53 HCC patients relative
to other HCC patients (p = 3.6 3 104 and p = 5.4 3 104,
respectively) (Figures 5A–5C), providing one possible mecha-
nism for low p53 signatures in non-TP53mutated HCC patients.
Tumors with low p53 target expression exhibited significant
associations with increased copy number instability (including
high-frequency chromosome 4q loss) (Rashid et al., 1999),
higher pathological grade, reduced expression of mature hepa-
tocyte marker genes, and increased risk of tumor recurrence
(Figure 5A). HCC patients within the lowest quartile p53 expres-
sion displayed a significantly reduced overall survival relative to
their high p53 signature counterparts (p = 0.0018) (Figure S5A).
Of three external HCC cohorts tested, two showed significantly
reduced overall survival of the low p53 signature patients (Fig-
ures S5B–S5D).
Among the p53-regulated HCC target genes, PTCHD4 had a
28-fold increased expression in the high expression quartile rela-
tive to the low p53 expression quartiles (Figure 5A). PTCHD4
suppresses sonic hedgehog (SHH) signaling in colorectal can-
cers (Chung et al., 2014) and SHH signaling is important in liver
regeneration. SHH pathway gene expression was significantly
upregulated in low p53 signature tumors by GSEA analysis.
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Figure 5. P53-Induced Gene Target Expression Signature for Improved Clustering of HCC Molecular and Biological Attributes
(A) Clustering of 191 HCC cases by composite expression of known p53 target genes. An expression heatmap of 20 p53-induced target genes is shown above
that of 10 p53-repressed target genes. To the right are shown mean expression ratios of top quartile p53 target genes relative to bottom quartile. Asterisks
indicate level of significance. ***p < 1E-10, **p < 1E-07, *p < 1E-04. Above the p53 target heatmap asterisks indicate tumors with a TP53mutation. Top bars show
molecular and clinical attributes and correlation (p values) with high and low p53 target gene expression. MDM4 copy number and expression are significantly
increased in those HCC patients with wild-type TP53 and with low p53 target expression relative to all other HCC patients (p values with asterisks).
(B) Frequent copy number amplification ofMDM4 gene in HCC. A segment of chromosome 1 centered on theMDM4 locus (in black box) is shown. The intensity of
red bars corresponds to degree of copy number gain. Each horizontal line corresponds to a single tumor.
(C) MDM4 copy number gain and amplification correlates with increased RNA expression. RNA expression for each tumor is represented by a red dot (mutant
TP53) or blue dot (WT TP53) according to MDM4 copy number (1 = deletion, 0 = diploid, 1 = copy number gain, 2 = amplification).
See also Figure S5.Another p53-repressed target gene, EZH2, was significantly up-
regulated in low p53 signature HCC (Figure 5A). EZH2 encodes a 
histone methyltransferase that epigenetically regulates stem cell 
maintenance (Vo¨ lkel et al., 2015) and its enhanced expression in 
low p53 signature HCC coincides with increased stem/progeni-
tor gene expression (Figure 5A). The low p53 signature HCC had 
increased expression of the p53-repressed cell cycle positive 
regulatory genes CCNB1/2, E2F2/3, and FOXM1. We hypothe-
size that p53 regulates HCC phenotypes in part through the SHH 
pathway via upregulated PTCHD4, the Polycomb repres-sive complex 2 via downregulated EZH2, and downregulation
of S/G2/M promoting cell cycle genes.
Other Signaling Pathways
Althoughmost gene and pathway alterations were evenly distrib-
uted with respect to iCluster classification, some mutations,
such as TERT and CTNNB1, were under-represented in iClust1
(Figure 6, Figures S6A and S6B). As described in previous
HCC genomics studies, WNT pathwaymembers were frequently
mutated or subject to copy number alterations. Overall, 44% of
Figure 6. Integrated Molecular Comparison of Somatic Alterations in Signaling Pathways across iCluster Groups
Each gene box includes three percentages representing the frequency of activation or inactivation in iClusters 1, 2, and 3 based on the core 196 sample HCC
dataset. All somatic changes are tallied together in calculating the percentages of altered cases within each of the iCluster sample groups. Somatic alterations
include mutations and copy-number changes (homozygous deletion and high-level amplifications), as well as epigenetic silencing of CDKN2A. Missense mu-
tations are only counted if they have known oncogenic function, have been reported in COSMIC, or occur at known mutational hotspots. Genes are grouped by
signaling pathways, with edges showing pairwise molecular interactions.
See also Figure S6.HCC displayed gene alterations in the WNT signaling axis. Other
key pathways included cell cycle regulatory pathways driven by
mutations and copy number changes in RB1,CCND1,CDKN2A,
and RTK/PI-3 kinase signaling driven by PTEN, PIK3CA, MET,
and VEGFA copy number or mutational changes. Chromatin
modifiers such as BAP1, ARID1A, and ARID2 were SMGs.
As an alternative to using SMGs, we employed a computa-
tional method to identify signaling pathways that displayed
enhanced mutation frequencies across all component genes of
that pathway, though each individual gene might not be signifi-
cantly mutated (STAR Methods, Pathway-Associated High
Impact Gene Mutations). We tested Reactome pathways for abias toward evolutionarily conserved nonsynonymous muta-
tions. We identified for each pathway the set of genes that
maximized bias toward high evolutionary action (EA) mutation
scores (a measure of relative evolutionary conservation)
compared to the cohort background (q < 0.05; Figures S7A–
S7H) (Katsonis and Lichtarge, 2014). Sets that exhibited signifi-
cant bias after false discovery rate (FDR) correction and were
more significant than 95% of simulations of similar sized path-
ways, were considered to be of interest and to point toward
cellular functions whose disruption may be advantageous to
the tumor (Table S7). Seven of the ten highest-ranked pathway
groups contained RAS, RAF, MAPK, PI3K, SOS, and SHC genes
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Figure 7. Characterization of Immune Microenvironment using RNA-Seq Data
(A) Unsupervised hierarchical clustering of gene expression identifies immune profiles within HCC patients. 66 manually curated immune cell markers were used
for clustering.
(B) The CIBERSORT-inferred relative fractions of different immune cell types varied across tumor and tumor adjacent normal samples and were not associated
with virus status.
(C) CIBERSORT cellular composition analysis revealed striking differences in relative compositions of immune cell populations between tumor and tumor-
adjacent normal tissues. p values were calculated byWilcoxon rank-sum test and adjusted for multiple testing (q value). The red dotted lines on the y axis indicate
q value of 0.01. The red dotted lines on the x axis indicate Z score of 0. The analysis was performed for all CIBERSORT immune cell types but only the significant
ones are labeled on the plot.and implicated pathways downstream of receptor tyrosine ki-
nases (RTKs) (Figures S7C–S7H, Table S7). The over-represen-
tation of pathways related to RTK signaling may be related to the 
sensitivity of HCC to the RTK inhibitor sorafenib and regorafenib.
Immune Phenotyping
Histopathological analyses of our core set of 196 HCCs revealed 
that 22% displayed high or moderate levels of lymphocyte infil-
tration. Given the recent success for targeted therapies against 
immune checkpoint genes such as CTLA-4, PD-1 (PDCD1), 
and PD-L1 (CD274), we characterized the immune microenviron-
ment in HCC. We first performed unsupervised hierarchical clus-
tering of gene expression by using a curated list of 66 immune 
markers that encompass cell surface markers of different im-
mune cell populations (Figure 7A). Expression of the immune 
markers varied greatly across HCC and tumor adjacent normaltissues. Unsupervised clustering identified six clusters of tumor
samples, with the High 1 and High 2 clusters exhibiting high
expression of the 66 immune markers, including the immune
checkpoint genes CTLA4, PDCD1 (PD-1), and CD274 (PD-L1).
No significant association was observed with HBV or HCV infec-
tion status. Likewise, overall survival was not significantly related
to immune clustering.
We further investigated the cellular composition of immune in-
filtrates in HCC cases by using the CIBERSORT (Newman et al.,
2015) inferred relative fractions of different immune cell types.
The immune compositions varied largely across samples (Fig-
ure 7B). We observed similar patterns of immune composition
between HBV+ and HCV+ tumors (p > 0.05) and between
HBV- or HCV-infected and virus-negative tumors (p > 0.05). Sig-
nificant differences in immune cellular composition between
tumor and tumor-adjacent normal samples were detected,
regardless of virus infection status (Figure 7C). In tumors, we
observed depletion of naive B cells, activated mast cells (virus+
tumors only), neutrophils, monocytes, gamma delta T cells, and
the activated (M2) macrophages (virus+ tumors only), and a sig-
nificant enrichment of memory B cells, suppressive regulatory
T cells (Tregs), resting mast cells, resting dendritic cells, and un-
differentiated (M0) macrophages (Figure 7C). The ratios of CD8/
Treg were significantly decreased in HCC tumors (p = 1.9e7).
These results indicated a transformation of the immunemicroen-
vironment in HCC tumor tissues from activating effector cells to
resting suppressive immune cells.
DISCUSSION
This comprehensive integrated analysis of HCC enhances our
understanding of the molecular events relevant to this cancer.
The utilization of six distinct data platforms in the current study
has facilitated integrated solutions not possible with single plat-
form studies. The robust statistical power provided by a rela-
tively large patient set of 363 HCC enabled us to identify 26
SMGs through use of the MutSigCV algorithm. Eight of these
26 SMGs had not been identified in previous HCC genomic
sequencing studies (Table S2B). Two, LZTR1 and EEF1A1, con-
tained somatic mutations identical to those recurrently observed
in other cancers. Two genes, SF3B1 and SMARCA4, exhibited
near significance byMutSigCV analysis and displayedmutations
identical to those identified as driver mutations in other cancers
(Tables S2A and S2B).
Among the SMGs identified in our HCC dataset were the ALB
and APOB genes, key mediators of hepatocyte function in the
secretion of blood factors albumin and VLDL. These functions
demand a high fraction of hepatocyte transcriptional, transla-
tional, and energy resources, and thus these processes might
be suppressed by the malignant hepatocyte to support cell divi-
sion requirements. We also noted that a high fraction of HCC
exhibited CPS1 hypermethylation accompanied by decreased
RNA expression. CPS1 encodes a rate-limiting enzyme for the
urea cycle, allowing more efficient removal of ammonia from
the body. Reduction of CPS1 could result in shunting of gluta-
mine to initiation of de novo pyrimidine synthesis, consistent
with increased CAD and decreased CPS1 expression levels
observed in HCC relative to normal hepatocytes. Thus, a key
component in the progression of hepatocytes to malignant
HCC cells may be metabolic reprogramming through either
genetic (ALB, APOB), epigenetic (CPS1), or other mechanisms,
converting a cell committed to normal organismal support func-
tions to a cell that supports only its own requirements for growth
and division.
Thesemutation and pathway analyses provide potential direc-
tions for future therapeutic efforts. We showed that WNT or p53
signaling or the telomerase promoter are altered in 77% of HCC
patients. WNT pathway small molecule inhibitors are currently in
preclinical and clinical development (Pez et al., 2013). Because
p53 can be rendered dysfunctional by alterations in upstream
regulator function (e.g., MDM2, MDM4), p53 signature analysis
may provide a more accurate representation of p53 functional
activity and may better predict clinical outcomes than muta-
tion-based studies. A fraction of HCC patients with WT TP53have elevated MDM4 expression, and currently available
MDM4 small molecule inhibitors might be efficacious in these
HCC cases (Jochemsen, 2014). The high frequency of TERT pro-
moter mutations suggests that upregulated TERT expression in
HCC might be targeted with telomerase inhibitors currently in
development (Ruden and Puri, 2013).
IDH1/2 mutations were observed in four HCC patients. The
recent development of IDH1 small molecule inhibitors suggests
these drugs may be useful in that minority of HCC patients
with IDH mutations (Okoye-Okafor et al., 2015). Although these
tumors histopathologically most closely resemble HCCs, they
exhibit clinical and genetic features of both cholangiocarcino-
mas andHCCs, signifying their possible origin frombiphenotypic
stem cells and suggesting that cholangiocarcinoma and HCC
represent two ends of a continuum. Hence, the presence of
IDH1/2mutations in HCC may be associated with a shift toward
a biliary phenotype, molecularly, even when the tumors do not
resemble mixed tumors by histopathology. The discovery of an
expression signature associated with this mutant, found in vary-
ing intensity in approximately 10%of the patients in several inde-
pendent cohorts, supports this view.
Focal HCC amplification events also revealed potential thera-
peutic targets. Amplification of MET and VEGFA loci indicates
that other RTK inhibitors, in addition to sorafenib, may be effec-
tive in HCC. MCL1, frequently amplified in HCC as well as in
many other tumor types, encodes an anti-apoptotic protein
that induces resistance to several chemotherapeutic agents
(Belmar and Fesik, 2015). Numerous small moleculeMCL1 inhib-
itors have been developed andmight be tested in corresponding
MCL1 amplified HCC patients (Belmar and Fesik, 2015).
Immune phenotyping of HCC by histopathology and gene
expression analyses of immune cell markers revealed that a sub-
set of HCC patients had high levels of immune cell infiltration.
The transformation of the immune microenvironment in some
HCC patients from activating effector cells to resting suppres-
sive immune cells suggests that therapies targeting the immune
checkpoint inhibitors (e.g., CTLA4, PD-1, PD-L1) in HCC might
lead to robust responses in those HCC patients with moderate
to high levels of immune cell infiltration (Prieto et al., 2015).
In conclusion, integrated analytic approaches have been
applied tomultiple data platforms from a large set of clinically an-
notated HCC cases to provide a better understanding of molec-
ular targets that may lead to improved therapeutic strategies.
The many identified targets indicate that it may be unlikely that
one agent can effectively target all or most HCC, and the most
effective treatments may entail multiple agents that specifically
attack different identified targets.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Sample Acquisition
The Tissue Source Sites (TSS) contributing biospecimens included in this manuscript include: ABS, Asterand, Baylor, St. Joseph’s
Medical Center Cancer Institute, Christiana Care Health Services, Emory University, Fox Chase Cancer Center, Hartford Hospital,
International Genomics Consortium, ILSbio, LLC., Mayo Clinic, Montefiore Medical Center, Ontario Institute for Cancer Research -
Ottawa, Roswell Park Cancer Institute, Saint Mary’s Health Care, St. Joseph - Arizona, University of Calgary Alberta Health Services,
University of California San Francisco, University of Florida, University of Michigan, University of Minnesota, University of North
Carolina, University of Pittsburgh, and University of Utah.
Approximately 86%of hepatocellular carcinoma cases (consisting of a primary tumor and a germline control) submitted to the BCR
and processed passed quality control metrics. Tumor tissue from 184 cases was submitted for reverse phase protein array analysis.
The data freeze included 196 cases from LIHC batches 100, 131, 153, 173, 203, 231, 275, 287, 303, 314, 327, 341, 345, and 365.
A descriptive table of clinical features, histological features, andmolecular features for the 196 case cohort as well as a patient level
summary are shown in Tables S1A and S1B. A post-freeze set of 167HCC cases were also examined by exome sequencing andDNA
copy number analysis and these are listed in Table S1C.
Sample Inclusion Criteria
Surgical resection of biopsy biospecimenswere collected frompatients diagnosedwith hepatocellular carcinoma (HCC), and had not
received prior treatment for their disease (ablation, chemotherapy, or radiotherapy). Institutional review boards at each tissue source
site reviewed protocols and consent documentation and approved submission of cases to TCGA. Cases were staged according to
the American Joint Committee on Cancer (AJCC). Each frozen primary tumor specimen had a companion normal tissue specimen
(blood or blood components, including DNA extracted at the tissue source site). Adjacent tissue was submitted for some cases.
Specimens were shipped overnight using a cryoport that maintained an average temperature of less than 180C.
Pathology quality control was performed on each tumor and normal tissue (if available) specimen from either a frozen section slide
prepared by the BCR or from a frozen section slide prepared by the Tissue Source Site (TSS). Hematoxylin and eosin (H&E) stained
sections from each sample were subjected to independent pathology review to confirm that the tumor specimen was histologically
consistent with the allowable hepatocellular carcinomas and the adjacent tissue specimen contained no tumor cells. Adjacent tissue
with cirrhotic changes was not acceptable as a germline control, but was characterized if accompanied by DNA from a patient-
matched blood specimen. The percent tumor nuclei, percent necrosis, and other pathology annotations were also assessed. Tumor
samples withR 60% tumor nuclei and% 20% or less necrosis were submitted for nucleic acid extraction.
METHOD DETAILS
Sample Processing
RNA and DNA were extracted from tumor and adjacent normal tissue specimens using a modification of the DNA/RNA AllPrep kit
(QIAGEN). The flow-through from the QIAGEN DNA column was processed using amirVana miRNA Isolation Kit (Ambion). This latter
step generated RNA preparations that included RNA < 200 nt suitable for miRNA analysis. DNA was extracted from blood using the
QiaAmp blood midi kit (QIAGEN).
RNA samples were quantified by measuring Abs260 with a UV spectrophotometer and DNA quantified by PicoGreen assay. DNA
specimens were resolved by 1% agarose gel electrophoresis to confirm high molecular weight fragments. A custom Sequenom SNP
panel or the AmpFISTR Identifiler (Applied Biosystems) was utilized to verify that tumor DNA and germline DNA representing a case
were derived from the same patient. Five hundred nanograms of each tumor and normal DNA were sent to QIAGEN (Hilden, Ger-
many) for REPLI-g whole genome amplification using a 100 mg reaction scale. RNA was analyzed via the RNA6000 nano assay
(Agilent) for determination of an RNA Integrity Number (RIN), and only analytes with RINR 7.0 were included in this study. Only cases
yielding a minimum of 6.9 mg of tumor DNA, 5.15 mg RNA, and 4.9 mg of germline DNA were included in this study.
Samples with residual tumor tissue were considered for proteomics analysis. When available, a 10 to 20 mg piece of snap-frozen
tumor adjacent to the piece used for molecular sequencing and characterization was submitted to MD Anderson for reverse phase
protein array analysis.
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Pathology Review
Standard Review of HCC
Each case had a single digital image of a full scan of an H&E slide available for review. The digital image had a magnification tool
that allowed examination of the image at various magnifications. The background liver was not consistently available for review.
Each case was reviewed independently by at least 3 liver pathologists, with no clinical or molecular information. Each pathologist
has specialty training in liver pathology and extensive experience in diagnostic pathology research. Pathologists had as much time
as they needed to review the digital images. The histological data collection sheet had been previously designed and discussed by
the participating pathologists. Prior to case review, representative examples of tumor grade and other select histological param-
eters were circulated in a PowerPoint as a reference guide. Each image was first reviewed to ensure the tumor was consistent with
a hepatocellular carcinoma; tumors inconsistent with hepatocellular carcinoma were not further reviewed. After that, the histolog-
ical data outlined below was collected and submitted through a web based interface. After data submission, the data were re-
viewed and finalized. For numerical data, the median score was used. For classification data, the majority pathology opinion
was used. Tumor grade was scored for both the predominant grade and the least differentiated grade using the following
definitions:
d Very well differentiated hepatocellular carcinoma: the cytological findings resemble non-neoplastic liver and the H&E differen-
tial includes hepatic adenoma, with no more than focal and minimal cytological atypia, and with no architectural atypia.
d Well differentiated hepatocellular carcinoma: the tumor shows unequivocal hepatic differentiation on H&E. There is mild but
definite cytological atypia and mild architectural atypia.
d Moderately differentiated hepatocellular carcinoma: the tumor is clearly cancer based on H&E and the cytological evidence for
hepatic differentiation is clear, or hepatic differentiation is strongly suspected from H&E. Moderate cytological and or architec-
tural atypia is present.
d Poorly differentiated hepatocellular carcinoma: hepatic differentiation is only suspected or is unclear from the H&E findings.
There is marked cytological and or architectural atypia.
Hepatocellular carcinomas have a number of different growth patterns, but most fall into the categories of solid, pseudoacinar, 
trabecular, or macrotrabecular (trabeculae at least 10 cells in thickness). The predominant pattern was chosen, as well as all other 
patterns that made up at least 5% of the tumor image.
The tumors were also extensively characterized by their cytological findings. The percent of the tumor with macrovesicular stea-
tosis, glycogen accumulation (clear cell change), hyaline bodies, and Mallory-Dank bodes were estimated to the nearest 10%. 
Ballooned hepatocytes were scored as none, few, or many. Lymphocytic and neutrophilic intratumoral inflammation was scored 
separately. Tumors with no or minimal inflammation were scored as 0. Greater degrees of inflammation were scored as mild, 
moderate, or marked, with marked inflammation defined as tumors with more inflammatory cells than tumor cells. When cholestasis 
was present, it was scored as mild (less than 5% of tumor area), moderate (6%–50% of tumor area), or marked (greater than 50% of 
tumor area). When scoring intratumoral fibrosis, broad bands of fibrosis that occasionally transverse tumors were not scored and 
scoring instead focused on capturing ‘‘pericellular’’ or intratumoral patterns of fibrosis. These areas were then scored as none or min-
imal, mild (intratumoral fibrosis less than 5%–25% of surface area), moderate (26 to 50% of surface area), or marked (fibrosis is equal 
to or greater than the amount of tumor cells)
Tumors were evaluated, on a yes/no basis, for the presence of clearly distinct nodules of HCC with different morphological pat-
terns. The goal was to capture those tumors that have multiple, clearly distinct morphologies on the submitted image. The distinct 
morphologies are found as separate tumor nodules with clearly delineated borders and this finding is a separate observation from 
growth pattern.
Finally, tumors were classified into specific subtypes, when possible, using the definitions below. Hepatocellular carcinomas that
did not fit into any of these categories were classified as ‘‘No Specific Subtype’’:
1. Biphenotypic hepatocellular carcinoma (combined hepatocellular and cholangiocarcinoma). There should be a portion of the
tumor that morphologically shows cholangiocarcinoma and a separate component that clearly shows hepatocellular
carcinoma.
2. Cirrhotomimetic hepatocellular carcinoma. This tumor is defined by its growth pattern with tumor nodules that mimic cirrhotic
nodules.
3. Clear cell hepatocellular carcinoma. This subtype was defined as carcinomas with at least 50% clear cell change.
4. Fibrolamellar carcinoma. This tumor is defined as having large polygonal eosinophilic cells with prominent nucleoli and intra-
tumoral fibrosis. It’s recognized that cases need immunostains to confirm this diagnosis in clinical practice, but the goal was
to identify cases with the classic morphological findings.
5. Granulocyte colony stimulating factor hepatocellular carcinoma. These are moderately to poorly differentiated hepatocellular
carcinomas with generally solid growth patterns and striking neutrophilic infiltrates. It is recognized that clinical correlation
with the white blood cell count is needed to confirm the diagnosis in clinical practice, but the goal was to identify cases
with the classic morphological findings.
6. Lymphocyte rich hepatocellular carcinoma. This subtype was defined as hepatocellular carcinoma having intratumoral lym-
phocytes with a density where the lymphocytes are similar or greater in number than tumor cells, and this finding is present in
more than 50% of the tumor image
7. Myxoid hepatocellular carcinoma. This tumor has sinusoids distended by myxoid material. At least 10% of the image should
show this finding.
8. Sarcomatoid hepatocellular carcinoma. The spindle cell component should make up at least 10% of the tumor image.
9. Scirrhous hepatocellular carcinoma. Intratumoral fibrosis makes up greater than 50% of the tumor image.
10. Steatohepatitic hepatocellular carcinoma. This subtype is defined by at least 33% fat, plus ballooned tumor cells that
resemble ballooned hepatocytes in steatohepatitis, plus at least mild tumor inflammation. Intratumoral fibrosis may be pre-
sent but is not required.
The pathology review has limitations imposed by the logistics of this study. One major limit stems from examining a single digital
image of a single tumor section, which has risk of sampling effects. This limit is particularly relevant to tumor sub-classification. As
one example, fibrolamellar carcinomas can have histological heterogeneity, and the classic findings may not be evident on the
scanned slide. As a second example, the requirement for 50% clear cell change to qualify for a clear cell hepatocellular carcinoma
is typically applied to the composite percentage of the sections from the entire tumor, and not a single slide. An additional limitation
was the inability to consistently collect data on the background, non-neoplastic liver tissues. Finally, diagnostic pathology in clinical
practice relies on the combination of morphology and immunohistochemical stains to render the final tumor classification. Immuno-
histochemically stained slides were not available in this study.
Review of IDH1/2 Mutated Patients
IDH1/2 mutations are frequent in intrahepatic cholangiocarcinomas (CCA) but rare or possibly noexistant in HCC; hence the possi-
bility that these tumors actually represented mixed HCC-CCA or intrahepatic CCAs was considered. First, we reviewed the original
pathology report from the tissue source site. The tissue source sites performed the initial pathologic review on the tumor slides and
also the surrounding normal liver tissue. They had access to the whole tumor and examined multiple sections before making a diag-
nosis. They only submitted tissue to the TCGA LIHC project after confirming the diagnosis of HCC. All four of them had been histo-
logically diagnosed as hepatocellular carcinoma and not as mixed HCC-CCA or cholangiocarcinoma. One of the tumors was poorly
differentiated; the tissue source site performed albumin in situ hybridization, which was positive, and hence they leaned toward diag-
nosis of HCC. Subsequently, our TCGA pathology review committee of experienced liver pathologists reviewed submitted images of
the H&E slides to independently confirm the diagnosis of HCC. Due to the constraints of the TCGA project process, the pathology
review committee did not have access to all slides and blocks from the tumor and were unable to perform additional immunohisto-
chemical analyses of the tumors. Based on the diagnosis of HCC from the tissue source site and its concordance with our indepen-
dent pathology review we believe that these 4 tumors are likely to be HCC.
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DNA Sequencing and Analysis
Primary DNA Sequencing
Primary DNA exome sequencing was carried out at the Human Genome Sequencing Center at Baylor College of Medicine using
approaches standard to TCGA and identical to those described by Totoki et al. (2014). Paired-end DNA sequence libraries were
generated following the standard HGSC protocol (http://www.hgsc.bcm.edu/sites/default/files/documents/Illumina_Barcoded_
Paired-End_Capture_Library_Preparation.pdf). Exome capture was performed by pooling 4 samples together into pre-pooled
libraries and then capturing with the HGSC VCRome 2.1 capture reagent (42Mb, NimbleGen). Library capture, amplification condi-
tions, and quality control were identical to those described in Totoki et al. (2014). Sequencing was performed on the Illumina HiSeq
2000 platform with one pool perlane following standard protocols identical to those in Totoki et al. (2014). Sequence runs generated
between 300-400 successful reads per lane.
Initial sequence analysis was performed by aligning reads to the human genome reference sequence hg19 using theMercury Pipe-
line (https://www.hgsc.bcm.edu/software/mercury) exactly as described by Totoki et al. (2014). Once aligned and following base
quality recalibration and indel realignment via the Mercury Pipeline, sequence alignment files (BAM files) were checked for contam-
ination by testing the concordance between SNPs in the tumor/normal pairs to the genotypes in the matching SNP Array from the
Broad Institute copy number platform. Samples with greater than 5% contamination are annotated and not used for subsequent
analyses. Sequence coverage averaged 100X for the cohort, with > 90% of target bases covered at 20X or greater in all samples.
All BAM files were submitted to CGHub.
Validation Sequencing
Validation sequencing was performed using the Ion Proton platform targeting 3865 amplicons using the AmpliSeq targeted
sequencing approach exactly as described by Totoki et al. (2014). Library construction, sequence generation, sequence alignment,
and validation criteria were identical to those used by Totoki et al. (2014).
Multi-Center Mutation Calling
Mutations were called by five production or analysis centers within the TCGA Network: Human Genome Sequencing Center
(Comprehensive And Reproducible Nucleotide Alterations in Cancer–CARNAC), UCSC (RADIA), BCGSC (Strelka), and Broad Insti-
tute (MuTect) as described below.
HGSC CARNAC: Mutations were called as described for the HGSC in Totoki et al. (2014).
UCSC RADIA: Single nucleotide somatic mutations were identified by RADIA (RNA AND DNA Integrated Analysis) (Radenbaugh
et al., 2014), a method that combines the patient matched normal and tumor DNA whole exome sequencing (DNA-WES) with the
tumor RNA sequencing (RNA-seq) for somatic mutation detection (software available at: https://github.com/aradenbaugh/radia/).
The inclusion of the RNA-seq data in RADIA increases the power to detect somatic mutations, especially at low DNA allelic fre-
quencies. By integrating the DNA and RNA, mutations that would be missed by traditional mutation calling algorithms that only
examine the DNA can be rescued back. RADIA classifies somatic mutations into 3 categories depending on the read support
from the DNA and RNA: 1) DNA calls – mutations that had high support in the DNA, 2) RNA Confirmation calls – mutations
that had high support in both the DNA and RNA, 3) RNA Rescue calls – mutations that had high support in the RNA and weak
support in the DNA. Here RADIA identified 32,113 DNA mutations, 6,315 RNA Confirmation mutations, and 741 RNA Rescue
mutations.
BCGSC Strelka (Saunders et al., 2012) (v1.0.6) was used to identify somatic single nucleotide variants, and short insertions and
deletions from the TCGA LIHC exome dataset. All parameters were set to defaults, with the exception of ‘‘isSkipDepthFilters,’’ which
was set to 1 in order to skip depth filtration given the higher coverage in exome datasets. 202 pairs of libraries were analyzed. When a
blood sample was available, it served as the matched normal specimen; otherwise, the matched normal tissue was used. The var-
iants were subsequently annotated using SnpEff, and the COSMIC (v61) and dbSNP (v137) databases.
MD Anderson-Baylor College of Medicine: MuSE: We developed a novel approach to mutation calling based on the Markov sub-
stitution model for molecular evolution, which models the evolution of the reference allele to the allelic composition of the matched
tumor and normal tissue at each genomic locus. To improve overall accuracy, we further adopt a sample-specific error model to iden-
tify cutoffs, reflecting the variation in tumor heterogeneity among samples.
Broad Institute: The Firehose pipeline (https://www.broadinstitute.org/cancer/cga/Firehose) performed additional quality control
(QC) on the BAM files, mutation calling, small insertion, and deletion detection and annotation of point mutations and indels as
follows:
1. QC onBAMfiles: The sample cross-individual contamination levels were estimated using the ContEst program (Cibulskis et al.,
2011). Tumor normal pairs of samples with contamination less than 4% were used further downstream for analysis.
2. Somatic mutation Calling and Significantly Mutated Genes: The MuTect algorithm (Cibulskis et al., 2013) was used to detect
somatic single nucleotide variants (SSNVs).
3. Small insertion and deletion detection: The Indelocator algorithm (https://www.broadinstitute.org/cancer/cga/indelocator)
was used to detect small indels.
4. Mutations and indels annotations: Point mutations and indels detected by respective MuTect and Indelocator were annotated
using utility namedOncotator (Ramos et al., 2015). Oncotator mapped somatic mutations to respective genes, transcripts, and
other relevant features. These annotations correspond to the fields in the Mutation Annotation Format (MAF) files version 2.4:
(https://wiki.nci.nih.gov/display/TCGA/Mutation+Annotation+Format+(MAF)+Specification).
Integrating Mutation Calls
Mutation calls from each center were integrated bymatched allele aggregation into amulti-center MAF file. The variant and reference
coverages for each allele were normalized by direct lookup in the respective BAM files for the samples. Coverages from RNA data
were also added for matched samples. Annotation was performed using the CARNAC annotation tools.
The final mutation set validation criteria were:
1. Accept Tumor validation based on RNA data if greater than two variant alleles observed in RNA and RNA variant allele fraction
was greater than 1%.
2. Accept Normal validation based on RNA data if greater than two variant alleles observed in RNA and RNA variant allele fraction
was greater than 0.2%.
3. Accept Tumor validation based on Proton data if greater than two variant alleles observed in validation sequence and validation
variant allele fraction was greater than 1%.
4. Reject Tumor validation based on Proton data if allele not Accepted by Proton data and the binomial test of allele fraction for
validation is significantly less than the allele fraction for the primary sequence.
5. Accept Normal validation based on Proton data if greater than two variant alleles observed in validation sequence and valida-
tion variant allele fraction was greater than 0.2%.
6. Accept Tumor validation if the allele was called by the Ion Variant Caller in tumor.
7. Accept Normal validation if the allele was called by the Ion Variant Caller in normal.
8. Final mutation and validation calls were made by integrating the above cases (1-7).
Mutation Significance Analysis
MutSig Suite: MutSig 2CV v3.1 (Lawrence et al., 2014), was applied to the consensusmutation call set filtered by the DNA allelic frac-
tion > = 0.025, to identify 12 significantly mutated genes (Figure 1), including TP53, CTNNB1, ALB, RB1, AXIN1, BAP1, ARID1A,
TSC2, IL6ST, APOB, HNF1A, and RPS6KA3 (FDR < 0.1). A list of all non-silent gene mutations is shown in Table S2A.
Inactivating SMG Analysis
For inactivating SMG analysis the raw MAF file was first filtered using the following filtering strategy; 1) variants were removed if they
appeared in a cohort of normal samples, 2) variants were removed if they were observed greater than 2 times in the matched normal
sample, had a variant allele fraction less than 0.04, if the gene had greater than 3 variants in the matched sample, or if the base
coverage of the normal sample was less than 6. From the filtered data, we compared the rate of inactivating variants (nonsense,
frameshift, splice-site) to all other variation. We report the Chi-square and Binomial test p values for the difference in the ratio of
inactivating variation in each gene compared with the background rate of the entire cohort (Table S2B).
TERT Promoter Sequencing
TERT promoter sequencing was performed by the Sanger sequencing method exactly as described by Totoki et al. (2014). Two
amplicons were attempted for each subject and the subject was considered to harbor a TERT promoter mutation if either amplicon
generated a positive SNP call. Both automated (via SNPDetector) and manual calling were employed. Cases that failed in amplicon
generation are encoded as NA for mutation status of the TERT-promoter. Samples with TERT-promoter status are present in
Table S3.
Mutation Signature Analysis
The mutation signatures discovery is a process of de-convoluting cancer somatic mutations, stratified by mutation contexts or bio-
logically meaningful subgroups, into a set of characteristic patterns (signatures) and inferring the contributions of discovered signa-
ture activity across samples. The common classification of SNVs is based on six base substitutions within the tri-nucleotide
sequence context including the bases immediately 50 and 30 to each mutated base. Six base substitutions (C>A, C>G, C>T, T>A,
T>C, and T>G) with 16 possible combinations of neighboring bases result in 96 possible mutation types. Thus the input data for
the mutation signature discovery is given as 96 byMmutation matrix (M = # of sample). Here we applied the Bayesian non-negative
matrix factorization algorithm (BayesNMF) (Kasar et al., 2015) to infer the number of mutational signatures and their sample-specific
contributions. Themutation count matrix was ingested as an input for the BayesNMF and factored into twomatrices,W’ (96 by K) and
H’ (K by 2M), approximating X byW’H’. Out of 50 Bayesian NMF runs with a half-normal prior forW’ and H’ seven runs converged to
the 2-signature solution, while 43 runs converged to the 3-signature solutions.We used the 3-signature solution (K = 3) in downstream
analyses (Sig A, Sig B, and Sig C in Figure S1A).
To enumerate the number of mutations associated with each mutation signature we performed a scaling transformation,
XW’H’ =WH,W=W’U-1 andH=UH’, whereU is a K by K diagonal matrix with the element corresponding to the 1-norm of column
vectors ofW’, resulting in the final signaturematrixW and the activity matrixH. Note that the kth column vector ofW (wk) represents a
normalizedmutability of 96 tri-nucleotidemutation contexts in the kth signature and the kth row vector of H (hk) dictates the estimation
of mutations associated to the kth signature across samples.
We used cosine similarity to compare our three signatures with thirty signatures (http://cancer.sanger.ac.uk/cosmic/signatures)
previously reported. Signature A of this study correspondsmost closely with published signature 22 and Bwith 24. A/22 is associated
with exposure to aristolochic acid (AA) and B/24with exposure to Aflatoxin B1 (AFB1). The etiology of signature C,which corresponds
to published signature 5 is unknown.
To identify samples with a significant enrichment of the activity of each mutational process we performed a hierarchical clustering
of a normalized signature activity (Figure S1B) using the standard R package with a ‘‘euclidean’’ distance and a ‘‘ward.D’’ linkage
option. Nine samples (Red in Figure S1A) were tightly clustered with a significantly higher activity of Sig A (aristolochic acid).
Twenty-five samples (Blue in Figure S1B) were clustered together with the increased activity of Sig B (aflatoxin B1). Interestingly,
six of the top seven samples with the highest activity of Sig B were the same as the AFB1-affected samples identified by the inde-
pendent mutation signature analysis for the 198 TCGA samples.
The enrichment analysis of splice site mutations on nine samples with a high activity of aristolochic acid (AA) signature (Figure S1B)
and aflatoxin B1 (AFB1) mutations in TP53 R249S mutant samples (Figure S1C) was accomplished by two-sided Wilcoxon rank-
sum tests.
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Identification of Pathogens
Microbial Detection in RNA-Seq Data
BioBloom Tools – BCCancer Agency: Ourmicrobial detection pipeline is based on BioBloomTools (BBT, v1.2.4.b1), which is a Bloom
filter-based method for rapidly classifying RNA-seq or DNA-seq read sequences (Chu et al., 2014). We generated 43 filters from
‘complete’ NCBI genome reference sequences of bacteria, viruses, fungi and, protozoa, using 25-bp k-mers and a false positive
rate of 0.02. We ran BBT in paired-end mode with a sliding window to screen FASTQ files from RNA-seq libraries (49-bp PE reads),
and whole exome libraries (49-bp PE reads). In a single-pass scan for each library, BBT categorized each read pair as matching the
human filter, matching a unique microbial filter, matching more than one filter (multi-match), or matching neither human nor microbe
(no-match). For each filter, we then calculated a reads-per-million (RPM) abundance metric as:
Abundance metric=

#reads mapped to the microbe
#reads mapped to human in the sample
 106

We applied a threshold of 2 RPM for identifying samples that were positive for hepatitis B.
PathSeq - Broad Institute: The PathSeq algorithm (Kostic et al., 2011) was used to perform computational subtraction of human
reads, followed by alignment of residual reads to a combined database of human reference genomes and microbial reference ge-
nomes (which includes but is not limited to Hepatitis B virus (HBV), Hepatitis C Virus (HCV) genomes), resulting in the identification
of reads mapping to HBV and HCV genomes in RNA sequencing data.
Subjects were classified as HBV-positive by RNA sequencing if at least 1 HBV read in 1 million human reads were present; other-
wise, subjects were classified as HBV-negative. In addition, subjects were classified as HCV-positive by RNA sequencing if at least 1
HCV reads in 1 million human reads were present; otherwise, subjects were classified as HCV-negative.
Using PathSeq, human reads were subtracted by first mapping reads to a database of human genomes using BWA (version 0.6.1),
Megablast (version 2.2.23), and Blastn (version 2.2.23). Only sequences with perfect or near perfect matches to the human genome
were removed in the subtraction process. To identify HBV / HCV reads, the resultant non-human reads were aligned with Megablast
to a database of microbial genomes that includes multiple HBV and HCV reference genomes. HBV / HCV reference genomes were
obtained from the NCBI nucleotide database (downloaded in June 2012).
Mayo Clinic: To identify viral insertions in these LIHC (HCC) TCGA DNA-seq and RNA-seq samples, we implemented a workflow
with BWA-mem that aligns pair-end reads to viral genomes. An in-house database of viral genomes was built from NCBI RefSeq viral
sequences. A set of custom scripts was written to identify reads pairs where one readmapped to the human genome and the second
read mapped to a viral genome. The workflow includes the following steps:
a. Read pairs with at least one read unaligned to the reference genomewere extracted from the TCGAGRCh37 aligned BAM files
for each sample.
b. The extracted read pairs were re-aligned to the human genome using BWA-mem. Read pairs where both reads mapped to the
human genome were filtered out.
c. The remaining reads were aligned to the viral genomes in our database using BWA-mem.
d. Concordant reads that mapped to viral genomes were extracted to compute coverage. Discordant and, if available, softclip-
ped read pairs where only one mate aligned to the human genome were combined and clustered based upon their proximity
within the human genome. The cluster cutoff was set to the average insert size of the library. Each cluster was reported as one
viral insertion event. The softclipped reads were further used to provide a more precise genomic location of the insertion.
Finally, insertion events with less than 10 supporting reads were filtered out before visually curating the remaining events using IGV.
Consensus virus calls: We deemed a sample positive for Hepatitis B or C if the calls from Broad, BC and Mayo were all above their 
respective thresholds, or if the clinical data from the tissue source site identified the sample as Hepatitis positive. We chose to main-
tain the clinical verdict even in cases for which no HBV or HCV was detected by computational methods due to the potential for the 
virus to have cleared spontaneously or in response to antiviral therapy before the onset of cancer. Using the thresholds determined by 
each center, 44 tumors and 8 adjacent normals were identified as HBV positive, while 31 tumors and 5 adjacent normals were 
deemed HCV positive. In every case where an adjacent normal sample was identified as HBV or HCV positive, the matched tumor 
was also positive.
Viral Integration Sites Inferred from RNA-Seq Data
BC Cancer Agency: To detect genomic integration of specific viruses we performed de novo assembly of RNA-seq and DNA-seq
sequence data with ABySS v1.3.4 (Simpson et al., 2009), using for each library the reads classified by BBT as human, the virus,
multi-match, and nomatch. We then merged the k-mer assemblies for each library with Trans-ABySS v1.4.8 to generate the working
contig set. We re-ran BBT on these contigs, applying only human and specific virus filters, identifying contigs that matched to both
filters. We identified any integration breakpoints in such multi-matched contigs by using BLAT v34 to align each contig to the human
GRCh37/hg19 reference sequence, and to virus reference sequences. We retained contig alignments in which: a) the aligned human
and viral sequences summed to at least 90% of the contig length, and b) the human and viral aligned overlapped by less than 50%.
Human breakpoint coordinates were annotated against RefSeq and UCSC (Kuhn et al., 2013) gene annotations (downloaded from
the UCSC genome browser on 30-Jun-2013). Breakpoints that had at least 3 spanning mate-pair reads or 5 flanking mate-pair reads
were considered potential integration sites.
We identified 27 tumors and 7 adjacent normals as having at least one HBV integration event. In contrast, we detected no HCV
integration events. HBV integrated into the human genome in approximately 77% of the samples in which HBV was detectable. In
two additional samples, TCGA-CC-A3MA and TCGA-ED-A7PZ, an integration event was detected despite HBV being below
threshold. The results are summarized in Table S5B.
Broad Institute:AnHBV-positive sample was considered integration positive if there were at least 5 spanning read pairs or 10 flank-
ing reads supporting an integration event. In case of HBV-positive, flanking read pairs were defined as having one end of the paired-
end read mapped to the HBV genome and its mate pair mapped to the human genome. Spanning reads were defined as having one
end of the paired end read spanning the integration junction and itsmate pair mapped to either the human or HBV genome. OnceHBV
reads were obtained, we extracted all mate pairs and used Tophat-2.0.8 (Trapnell et al., 2009) with fusion option enabled to map
these paired end reads to a combined database containing the human genome and anHBV genome. Next, spanning reads and flank-
ing reads are identified from the aligned BAM file.
Human genes involved in the integration are identified using the breakpoint coordinates based on RefSeq and UCSC gene anno-
tations (last modified on 30-Jun-2013) from the UCSC genome browser. Similar approach is followed for identification of HCV inte-
gration from RNaseq data. These results are summarized in Table S5B.
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Gene Fusion Detection
BCMHGSC: TCGA RNA sequencing data (RNA FastQ files) were downloaded for the 196 patients on this freeze list set from CGHub.
deFuse version 0.6.1 (McPherson et al., 2011) with default settings detected a large list of candidate fusion genes. The deFuse results
were filtered by removing events identified as ‘‘read through’’ transcription of adjacent genes, requiring coding regions, in-frame
(ORF) genes and samples with a defuse confidence score of > 80%. Our sample set included 11 tissue adjacent normal (TAN) sam-
ples; any fusions that were also identified in the TAN sample set were removed from analysis. To characterize the resultant candidate
fusion genes we did the following checks:
d Each read spanning a fusion junction was aligned to the reference genome using BLAT in the UCSC Genome Browser to
confirm their map locations. The fusions that mapped with 100% identity to each part of the identified fusion (gene1 or
gene2) were selected for further analysis. Genes that mapped to multiple locations were discarded.
d Each RNA BAM from candidate fusion genes was examined in IGV, to verify the presence of stacked soft clipped reads and
changes in coverage at the identified fusion breakpoints. The sequence of each soft clipped read was brought into the
UCSC genome browser and mapped using BLAT.
d The CBio data portal (http://www.cbioportal.org/) was used to examine copy number data and gene expression data for the
gene partners in each fusion identified.
d We also utilized copy number data, loading a given patient’s Affymetrix 6.0 .seg files into IGV in tandem with their RNA Seq
BAMS, to evaluate the DNA coverage along with soft clipped reads at the identified the mRNA break points. When whole
genome sequence BAMS were available for a given patient, we also included those in the evaluation.
MD Anderson: We used the Pipeline for RNaseq Data Analysis (PRADA) to preprocess RNA Seq data and detect gene fusions
(Torres-Garcı´a et al., 2014). PRADA aligns short reads to a composite reference database composed of whole genome sequence
(hg19) and transcriptome sequence (Ensembl64). By default, PRADA uses two criteria to select candidate fusions:
1) a minimum of two discordant read pairs mapping to a candidate gene pair, i.e., two distinct protein coding genes;
2) a minimum of one junction spanning read mapping to a hypothetical junction constructed from the candidate gene pair.
To construct a hypothetical junction, we used 40 base pairs from either side of two connecting exons, considering the RNaseq read
length is 48 base pairs in this dataset. All junction spanning reads and discordant reads allowed onemismatch. From these candidate
fusions, we filtered out those fusions that had significant sequence similarity (BLASTN, Expect value required to be > 0.01) (Altschul
et al., 1997). We then calculated the transcriptional allelic fraction (TAF) for each fusion partner. TAF was defined as the fraction of
fusion-associated junction spanning reads over all reads that spanned the involving exon boundaries. We required the minimum TAF 
to be 0.1 for at least one partner gene. Six fusions were included in the final list for their established roles in this cancer type or other 
cancers despite their lower TAFs. These six fusions included two TCF7L2-VTI1A fusions, three DNAJB1-PRKACA fusions and one 
FGFR3-TACC3 fusion. Prediction of fusion functional consequence (in-frame, out-of-frame, UTR-CDS, etc.) was performed by 
PRADA using the Ensembl64 defined gene/transcript model. Only fusions that involved coding regions (in-frame and out-of-frame) 
were retained for further analysis. More details of the PRADA pipeline were described (https://sourceforge.net/projects/prada/).
We analyzed 196 samples from the freeze list, from which we detected a total of 236 fusions. The number of fusions in each case 
ranged from 0 to 18. We compared fusions to a list of kinases from Uniprot (http://www.uniprot.org) and cancer genes from the Can-
cer Gene Census. Out of the 236 fusions 26 involved a kinase gene, and 27 involved a cancer gene. We further aligned the fusions to 
copy number data. We were able to find a copy number breakpoint for 201 fusions at the vicinity of 500 Kb using the copy number 
cutoff 0.1 (log ratio). One in-frame SLC12A7-TERT fusion, which had corroborating exon expression pattern and DNA breakpoints 
near both partner genes.
Mayo Clinic: We converted the TCGA LIHC RNASeq BAM files into FASTQ files and realigned them using the Mayo Analysis Pipe-
line for RNA Seq (MAP-RSeq) (http://bioinformaticstools.mayo.edu/research/maprseq/). MAP-RSeq uses tophat, a splice-junction 
aware aligner to map paired-end RNA sequencing reads. Tophat uses bowtie, a memory efficient short read aligner, to quickly 
map reads to a reference genome and transcriptome, and then uses those alignments to identify known and novel transcript ele-
ments within each sample. MAP-RSeq reports 2 fusion events lists, one that displays all possible fusion events detected by to-
phat-fusion, and a second enriched in confident fusion events using tophat-fusion’s default filtering strategy. Tophat-fusion’s default 
filtering strategy involves evaluating the number of supporting reads, the genes involved, the mapping uniqueness, and the dissim-
ilarity of the sequence around the fusion breakpoints to detect credible fusion events. The list that includes all possible fusion events 
was combined with fusions reported by other institutions to establish a consensus set of fusions. The filtered fusions list was used to 
suggest events for further validation. All fusion events were bioinformatically visualized and curated with IGV and circos plots.
Blueprint Medicines: Gene fusions in the LIHC dataset were discovered using methods previously described (Stransky et al., 2014). 
Briefly, the RNaseq fastq files were downloaded from CGHub and aligned using the STAR algorithm v2.3.1q (Dobin et al., 2013) with 
options described previously. Version hg19 of the human genome, as well as transcriptome and splice junction annotations from the 
Gencode project v17 were provided to the STAR algorithm as an alignment reference. Next, fusions between any two genes were 
identified based on the number of chimeric reads (sequencing paired ends mapping to different genes) and split reads (spanning 
a fusion breakpoint), concordance between the strands of the reads and the genes involved in the putative fusion, and a number 
of filtering criteria to flag false positive and non-functional fusions. In addition, recurrent kinase fusions observed in a panel of 600 
normal samples from TCGA and 1,800 normal samples from the Genotype–Tissue Expression (GTEx) project were also excluded 
from further analysis. Finally, all recurrent kinase fusions (n R 2) were manually reviewed to identify putative oncogenic drivers 
with distinctive characteristics of functional kinase fusions. In particular, the following features were required: presence of an inter-
genic junction between two exons, a predicted in-frame coding sequence and conservation of the complete kinase catalytic domain. 
Conversely, we excluded false positives from further analysis according to two main criteria: the presence of a homologous or repet-
itive sequence shared by the two fusion partners causing an alignment artifact, or the very high expression of one or both fusion 
partners.
Research Center for Advanced Science and Technology (RCAST): Recent observations of structural rearrangements involving 
TERT prompted us to specifically investigate TERT mRNA for evidence of fusion transcripts. We extracted all reads that mapped 
in 5p13.33 (chr5:1-2Mb) from the RNA-seq BAM files. Within this interval we searched for any paired-end reads that mapped 
more than 100kb apart or mapped to other chromosomes. Anomalous read pairs, which aligned within 10kb of TERT were extracted 
from RNaseq BAM file, and assembled. TERT-fusion candidates found in four samples were manually checked in Integrative Geno-
mics Viewer (IGV).
Contributors: Eve Shinbrot, Frederick M. Lang, Siyuan Zheng, Roeland G.W. Verhaak, Daniel O’Brien, Jean-Pierre Kocher, Nicolas 
Stransky, Hiroyuki Aburatani, Yamamoto Shogo.
SNP-Based Copy Number Analysis
DNA from each tumor or germline sample was hybridized to Affymetrix SNP 6.0 arrays using protocols at the Genome Analysis Plat-
form of the Broad Institute as previously described (McCarroll et al., 2008). Briefly, from raw .CEL files, Birdseed was used to infer a 
preliminary copy number at each probe locus (Korn et al., 2008). For each tumor, genome-wide copy number estimates were refined 
using tangent normalization, in which tumor signal intensities are divided by signal intensities from the linear combination of all normal 
samples that are most similar to the tumor. This linear combination of normal samples tends to match the noise profile of the tumor 
better than any set of individual normal samples, thereby reducing the contribution of noise to the final copy-number profile. Individual 
copy-number estimates then underwent segmentation using Circular Binary Segmentation (Olshen et al., 2004). As part of this pro-
cess of copy number assessment and segmentation, regions corresponding to germline copy-number alterations were removed by 
applying filters generated from either the TCGA germline samples from the ovarian cancer analysis or from samples from this collec-
tion. Segmented copy number profiles for tumor and matched control DNAs were analyzed using Ziggurat Deconstruction, an 
algorithm that parsimoniously assigns a length and amplitude to the set of inferred copy-number changes underlying each 
segmented copy number profile (Mermel et al., 2011). Significant focal copy number alterations were identified from segmented
data using GISTIC 2.0 (Mermel et al., 2011). For copy number based clustering, tumors were clustered based on thresholded copy
number at reoccurring alteration peaks fromGISTIC analysis (all_lesions.conf_99.txt file). Hierarchical clusteringwas done in R based
on Euclidean distance using Ward’s method. Purity, ploidy and whole genome doubling estimates were calculated using the
ABSOLUTE algorithm (Carter et al., 2012).
Contributors: Andrew D. Cherniack, Bradley A. Murray, Juliann Shih, Carrie Cibulskis.
DNA Methylation
Assay Platform
DNA methylation data were generated using the Illumina Infinium DNA methylation platform (Bibikova et al., 2011),
HumanMethylation450 (HM450). The HM450 assay analyzes the DNA methylation status of up to 482,421 CpG and 3,091 non-
CpG (CpH) sites throughout the genome. It covers 99% of RefSeq genes with multiple probes per gene and 96% of CpG islands
from the UCSC database and their flanking regions. The assay probe sequences and information for each interrogated CpG site
on Infinium DNA methylation platform are available from Illumina (https://www.illumina.com/).
The DNA methylation score for each assayed CpG or CpH site is represented as a beta (b) value (b = (M/(M+U)) in which M and U
indicate the mean methylated and unmethylated signal intensities for each assayed CpG or CpH, respectively. b-values range from
zero to one, with scores of ‘‘0’’ indicating no DNA methylation and scores of ‘‘1’’ indicating complete DNA methylation. A detection
p value accompanies each data point and compares the signal intensity difference between the analytical probes and a set of nega-
tive control probes on the array. Any data point with a corresponding p value greater than 0.05 is deemed not to be statistically signif-
icantly different frombackground and is thusmasked as ‘‘NA’’ in the Level 3 data packages as described below. Further details on the
Illumina Infinium DNA methylation assay technology have been described previously (Bibikova et al., 2011).
Sample and Data Processing
We performed bisulfite conversion on 1mg of genomic DNA from each sample using the EZ-96 DNAMethylation Kit (Zymo Research,
Irvine, CA) according to the manufacturer’s instructions. We assessed the amount of bisulfite-converted DNA and completeness of
bisulfite conversion using a panel of MethyLight-based quality control (QC) reactions. All the TCGA samples passed our QC tests and
entered the Infinium DNA methylation assay pipeline. Bisulfite-converted DNAs were whole-genome-amplified (WGA) and enzymat-
ically fragmented prior to hybridization to BeadChip arrays. BeadArrays were scanned using the Illumina iScan technology to
produce IDAT files. Raw IDAT files for each sample were processed with the R/Bioconductor package methylumi. TCGA DNA
methylation data packages were then generated using the EGC.tools R packagewhichwas developed internally and is publicly avail-
able on GitHub (https://github.com/uscepigenomecenter/EGC.tools).
TCGA Data Packages
The data levels and the files contained in each data level package are described below and are present on the TCGA Data Portal
website (https://tcga-data.nci.nih.gov/tcga/). Please note that as continuing updates of genomic databases and data archive revi-
sions frequently become available, the data packages on TCGA Data Portal are updated accordingly.
Level 1 data contain raw IDAT files (two per sample) as produced by the iScan system and as mapped by the SDRF. These IDAT
files were directly processed by the R/Bioconductor package methylumi. We provided a disease-mapping file (LIHC.mappings.csv)
in the AUX directory to facilitate this process. Level 2 data contain background-corrected methylated (M) and unmethylated (U) sum-
mary intensities as extracted by the R/Bioconductor package methylumi. Detection p values were computed as the minimum of the
two values (one per allele) for the empirical cumulative density function of the negative control probes in the appropriate color chan-
nel. Background correction was performed via normal-exponential deconvolution. Multiple-batch archives had the intensities in each
of the two channels multiplicatively scaled to match a reference sample (sample with R/G ratio of the normalization control probes
closest to 1.0). Level 3 data contain b-value calculations with annotations for HGNC gene symbol, chromosome, and genomic
coordinates (UCSC hg19, Feb 2009) for each targeted CpG/CpH site on the array. Probes having a common SNP (Minor Allele Fre-
quency > 0.01, per dbSNP build 135 via the UCSC snp135common track) within 10 bp of the interrogated CpG site or having a 15 bp
from the interrogated CpG site which overlapped with a repetitive element (as defined by RepeatMasker and Tandem Repeat Finder
Masks contained in the BSgenome.Hsapiens.UCSC.hg19 R package) were masked as ‘‘NA’’ across all samples, and probes with a
detection p value greater than 0.05 in a given sample were masked as ‘‘NA’’ on that array. Probes that were mapped to multiple sites
on hg19 were annotated as ‘‘NA’’ for chromosome and 0 for CpG/CpH coordinate.
The following data archives were used for the analyses described in this manuscript.
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.1.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.2.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.3.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.4.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.5.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.6.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.7.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.8.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.9.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.10.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.11.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.12.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.13.13.0
jhu-usc.edu_LIHC.HumanMethylation450.Level_3.14.13.0
Unsupervised Clustering Analysis
We removed probes which had any ‘‘NA’’-masked data points and probes that were designed for sequences on X and 
Y chromosomes.
To capture cancer-specific DNA hypermethylation events, we first selected CpG sites that were not methylated in normal tissues 
(mean b-value < 0.2). To minimize the influence of variable tumor purity levels on a clustering result, we dichotomized the data using a 
b-value of > 0.3 as a threshold for positive DNA methylation. The dichotomization not only ameliorated the effect of tumor sample 
purity on the clustering, but also removed a great portion of residual batch/platform effects that are mostly reflected in small varia-
tions near the two ends of the range of b-values. We also removed CpG sites that were methylated in leukocytes, a major source of 
contamination present in a tumor sample (mean b-value > 0.3). We then performed unsupervised hierarchical clustering on 37,848 
CpG sites that were methylated with that threshold in at least 5% of the tumors using a binary distance metric for clustering and 
Ward’s method for linkage. The cluster assignments were generated by cutting the resulting dendrogram. Figure 2A displays a heat-
map of the original b-values for randomly selected 15,000 CpG sites used in the hierarchical clustering. The CpG sites were displayed 
based on the order of unsupervised hierarchal clustering of the b-values using the Euclidean distance metric and Ward’s linkage 
method.
To investigate subgroups based on cancer-specific DNA hypomethylation, we first identified CpG sites that were highly methylated 
in normal tissues (mean b-value > 0.8). We dichotomized the data using a b-value of < 0.7 as a threshold for loss of DNA methylation. 
We then performed unsupervised hierarchical clustering based on CpG sites that had hypomethylation in at least 10% of the tumors. 
We identified three major clusters. The cluster assignments were generated by cutting the dendrogram. To a great extent, these three 
clusters correlated well with three molecular subtypes defined using iCluster (Figure S3C). Of particular interest is approximately one-
third of tumors (largely corresponding to iCluster 3) which appear to have an extreme DNA hypomethylation.
Identification of Epigenetically Silenced Genes
We first removed DNA methylation probes overlapping with SNPs, repeats or designed for sequences on X or Y chromosomes or 
non-CpG sites. The remaining probes were mapped against UCSC Genes using the GenomicFeatures R/Bioconductor package. 
Probes that were located in a promoter region (defined as the 3 kb region spanning from 1,500 bp upstream to 1,500 bp downstream 
of the transcription start site) were identified. Level 3 mRNA expression data were log2 transformed (log2 (RSEM+1)) and used to 
assess the gene expression levels associated with DNA methylation changes. DNA methylation and gene expression data were 
merged by Entrez Gene IDs. We used two different approaches to identify genes epigenetically silenced in HCC, as described below.
In the first method, we removed the CpG sites that were methylated in normal tissues (mean b-value > 0.2). We then dichotomised 
the DNA methylation data using a b-value of > 0.3 as a threshold for positive DNA methylation and eliminated CpG sites methylated in 
fewer than 5% of the tumor samples. For each probe/gene pair, we applied the following algorithm: 1) organize the tumors as either 
methylated (b R 0.3) or unmethylated (b < 0.3); 2) compute the mean expression in the methylated and unmethylated groups; 
3) compute the standard deviation of the expression in the unmethylated group. We then selected probes for which the mean expres-
sion in the methylated group was less than 1.64 standard deviations from the mean expression of the unmethylated group. We 
labeled each individual tumor sample as epigenetically silenced for a specific probe/gene pair if: a) it belonged to the methylated 
group and b) the expression of the corresponding gene was lower than the mean of the unmethylated group of samples. If there 
were multiple probes associated with the same gene, a sample that was identified as epigenetically silenced at more than half the 
probes for the corresponding gene was also labeled as epigenetically silenced at the gene level. The complete list of 171 genes iden-
tified as epigenetically silenced using this method is provided in Table S4A.
In the second approach to identify genes silenced by DNA methylation, we applied a previously described method (Noushmehr 
et al., 2010). Briefly, Student’s t tests for significant differences in DNA methylation between tumor and adjacent normal tissue 
were conducted across all CpG loci located in gene promoter regions. Separately, a t test was used to identify genes that were ex-
pressed at significantly different levels between tumor and adjacent normal tissue. The resulting p values were corrected using the 
Benjamini-Hochberg procedure. We identified 132 genes significantly hypermethylated (FDR-adjusted p < 0.0001 and mean b value 
difference > 0.1) and downregulated (FDR-adjusted p < 0.0001 and reduced more than two-fold) in tumors. For each gene, we 
selected the DNA methylation probe with the greatest mean expression difference between methylated (b R 0.3) and unmethylated 
(b < 0.3) groups. We then estimated the frequency of epigenetic silencing for each gene by counting the number of tumors belonging 
to the methylated group.
CDKN2A (p16INK4A) Epigenetic Silencing
CDKN2A epigenetic silencing calls were made using the exon level RNA-seq data. CDKN2A DNA methylation status was assessed in 
each sample based on the probe (cg13601799) located in the p16INK4 promoter CpG island. p16INK4 expression was determined 
by the log2(RPKM+1) level of its first exon (chr9:21974403-21975038). The epigenetic silencing calls for each sample were made by 
evaluating a scatterplot showing an inverse association between DNA methylation and expression.
Leukocyte Methylation Signature
The leukocyte methylation signature was calculated as described in Carter et al. (Carter et al., 2012).
Statistics
Statistical analysis and data visualization were carried out using the R/Biocoductor software packages (http://www.bioconductor.
org). Cancer-specific DNA methylation was assessed based on unpaired analyses, since matched normal tissues were available
for fewer than 25% of the tumor samples.
Contributors: Toshinori Hinoue, Peter W. Laird.
miRNA Sequencing
We generated microRNA sequence (miRNA-seq) data for 189 tumor samples and 47 normals using previously described methods
(Cancer Genome Atlas, 2012). To identify miRs that were differentially abundant, we ran unpaired two-class SAMseq analyses, with
an FDR threshold of 0.05. We assessed potential miRNA targeting for all 189 samples by calculating miR-mRNA Spearman corre-
lations with MatrixEQTL v2.1.1, using gene-level normalized abundance RNaseq (RSEM) data from Firehose (gdac.broadinstitute.
org). We calculated correlations with a p value threshold of 0.05, then filtered the resulting anticorrelations at FDR < 0.05. We
then extracted miR-gene pairs that corresponded to functional validation publications reported by MiRTarBase v4.5, for stronger
(luciferase reporter, qPCR, western blot) and weaker experimental evidence types.
We identified groups of samples with similar abundance profiles using unsupervised non-negative matrix factorization (NMF)
consensus clustering of reads-per-million (RPM) data for the 300 (25%) most-variant 5p or 3p miRBase v16 mature strands. We
chose a 5-cluster solution based on the peaks of the cophenetic and average silhouette width scores.
Contributors: Reanne Bowlby, Gordon Robertson, Denise Brooks.
mRNA Sequencing
Sequencing and quantification
One mg of total RNA was converted to mRNA libraries using the lllumina mRNA TruSeq kit (RS-122-2001 or RS-122-2002) following
the manufacturer’s directions. Libraries were sequenced 48x7x48bp on the Illumina HiSeq 2000. FASTQ files were generated by
CASAVA. RNA reads were aligned to the hg19 genome assembly using MapSplice 0.7.4 (Wang et al., 2010). Gene expression
was quantified for the transcript models corresponding to the TCGA GAF2.1 (https://tcga-data.nci.nih.gov/docs/GAF/GAF.hg19.
June2011.bundle/outputs/TCGA.hg19.June2011.gaf), using RSEM and normalized within-sample to a fixed upper quartile (Li and
Dewey, 2011). For further details on this processing, refer to Description file at the DCC data portal under the V2_MapSpliceRSEM
workflow (https://tcga-data.nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/tumor/lihc/cgcc/unc.edu/illuminahiseq_
rnaseqv2/rnaseqv2/unc.edu_LIHC.IlluminaHiSeq_RNASeqV2.mage-tab.1.15.0/DESCRIPTION.txt). FASTQ and BAM files are at
CGHUB (https://cghub.ucsc.edu). Quantification of genes, transcripts, exons, and junctions can be found at the TCGA Data Portal
(https://tcga-data.nci.nih.gov/tcga/).
mRNA Expression Clustering
Transcription levels quantified by RSEM were filtered to remove genes whose expression was quantified as zero by RSEM in more
than 75%of the tumor samples, reducing the set of genes from 20,531 to 15,951. Gene quantifications were subsequently log2 trans-
formed, with zero values set to missing. To identify genes whose expression was variable, the gene set was filtered to remove genes
that demonstrated a standard deviation below 2.0 across all tumor samples, resulting in a set of 1,868 genes with high variability in
expression. The log2 transformed expression values were then median centered prior to clustering analysis. Cluster analysis was
performed using ConsensusClusterPlus (Wilkerson and Hayes, 2010), using agglomerative hierarchical clustering with a 1-Pearson
correlation distances and resampling 80% of the samples for 1000 repetitions. The optimal number of clusters was determined using
the empirical cumulative distribution function plot.
Contributors: Eric Seiser, Katherine A. Hoadley.
Reverse-Phase Protein Array
RPPA Experiments and Data Processing
Protein was extracted using RPPA lysis buffer (1% Triton X-100, 50 mmol/L HEPES (pH 7.4), 150 mmol/L NaCl, 1.5 mmol/L MgCl2,
1 mmol/L EGTA, 100 mmol/L NaF, 10 mmol/L NaPPi, 10% glycerol, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L Na3VO4,
and aprotinin 10 ug/mL) from human tumors and RPPA was performed as described previously (Gonzalez-Angulo et al., 2011; Hu
et al., 2007; Tibes et al., 2006). Lysis buffer was used to lyse frozen tumors by Precellys homogenization. Tumor lysates were adjusted
to 1 mg/mL concentration as assessed by bicinchoninic acid assay (BCA) and boiled with 1%SDS. Tumor lysates weremanually serial
diluted in two-fold of 5 dilutionswith lysis buffer. An AushonBiosystems 2470 arrayer (Burlington, MA) printed 1,056 samples on nitro-
cellulose-coated slides (Grace Bio-Labs). Slides were probed with 202 validated primary antibodies followed by corresponding
secondary antibodies (Goat anti-Rabbit IgG, Goat anti-Mouse IgG or Rabbit anti-Goat IgG). Signal was captured using a
DakoCytomation-catalyzed system and DAB colorimetric reaction. Slides were scanned in CanoScan 9000F. Spot intensities were
analyzed and quantified using Microvigene software (VigeneTech, Carlisle, MA), to generate spot signal intensities (Level1data).The
software SuperCurveGUI (Hu et al., 2007), available at http://bioinformatics.mdanderson.org/Software/supercurve/, was used to
estimate the EC50 values of the proteins in each dilution series (in log2 scale). Briefly, a fitted curve (‘‘supercurve’’) was plotted with
the signal intensities on the y axis and the relative log2 concentration of each protein on the x axis using the non-parametric,monotone
increasing B-spline model. During the process, the raw spot intensity data were adjusted to correct spatial bias before model fitting.
AQCmetricwas returned for eachslide tohelpdetermine thequality of the slide: if the score is less than0.8ona0-1scale, the slidewas
dropped. Inmost cases, the stainingwas repeated toobtain ahighquality score. Ifmore thanone slidewas stained for an antibody, the
slide with the highest QC score was used for analysis (Level 2 data). Protein measurements were corrected for loading as described
(Hu et al., 2007) using median centering across antibodies (level 3 data). In total, 202 antibodies and 184 samples were used. Final
selection of antibodies was also driven by the availability of high quality antibodies that consistently pass a strict validation process
as previously described (Hennessy et al., 2010). These antibodies are assessed for specificity, quantification, and sensitivity (dynamic
range) in their application for protein extracts from cultured cells or tumor tissue. Antibodies are labeled as validated and use with
caution based on degree of validation by criteria previously described (Hennessy et al., 2010).
Two RPPA arrays were quantitated and processed (including normalization and load controlling) as described previously,
using MicroVigene (VigeneTech, Carlisle, MA) and the R package SuperCurve (version-1.3), available at http://bioinformatics.
mdanderson.org/OOMPA (Hu et al., 2007). Raw data (level 1), SuperCurve nonparameteric model fitting on a single array (level 2),
and loading corrected data (level 3) were deposited at the DCC.
Data Normalization
We performed median centering across all the antibodies for each sample to correct for sample loading differences. Those differ-
ences arise because protein concentrations are not uniformly distributed per unit volume. That may be due to several factors,
such as differences in protein concentrations of large and small cells, differences in the amount of proteins per cell, or heterogeneity
of the cells comprising the samples. By observing the expression levels across many different proteins in a sample, we can estimate
differences in the total amount of protein in that sample versus other samples. Subtracting themedian protein expression level forces
the median value to become zero, allowing us to compare protein expressions across samples.
Consensus Clustering
Weperformed consensus hierarchical clustering on the RPPA data. 1-Pearson correlation was used as the distancemetric andWard
was used as a linkage algorithm. The consensus clustering method clustered the samples and counted how frequently two samples
were in the same cluster. The bootstrap resampling analysis identified two robust sample clusters. A total of 184 samples and 202
antibodies were used in the analysis.
Contributors: Rehan Akbani, Shiyun Ling, Zhenlin Ju, Yiling Lu, Gordon Mills.
Integrative Clustering Using iCluster
To understand the subgroups formed by integrating various molecular platforms of HCC, we utilized iCluster, which formulates the 
problem of subgroup discovery as a joint multivariate regression of multiple data types with reference to a set of common latent vari-
ables that represent the underlying tumor subtypes (Mo et al., 2013; Shen et al., 2009).
Data Processing
Five molecular platforms, DNA copy number, DNA methylation, mRNA expression, miRNA expression and RPPA were provided as 
input to iCluster. Data were pre-processed using the following procedures. Copy number alteration data were derived from CBS 
segmented data from the Affymetrix SNP6.0 platform, and further reduced to a set of non-redundant regions as described (Mo 
et al., 2013). For the methylation data (Illumina Infinium 450k arrays), the median absolute deviation was employed to select the 
top 1000 most variable CpG sites after beta-mixture quantile normalization. Methylation probes with > 20% or more missing data 
and those corresponding to SNP and autosomal chromosomes were removed. For mRNA and miRNA sequence data, lowly ex-
pressed genes were excluded based on median-normalized counts, and variance filtering led to 1266 mRNAs and 258 miRNAs 
for clustering. mRNA and miRNA expression features were log2 transformed, normalized, and scaled before using as an input to 
iCluster.
Model Selection
The optimal combination of clusters was determined minimizing a Bayesian Information Criterion (BIC). An ‘elbow’ point was noted at 
K = 3, beyond which the BIC kept increasing and thus the 3-class solution was chosen.
Figure S3C shows that the results were highly comparable for individual unsupervised clustering versus integrative clustering, indi-
cating that the iCluster groupings represented the combined information of all platforms and lacked bias to a particular data type.
To compare the resultant iCluster groupings to the molecular subclasses developed by Hoshida (Hoshida et al., 2009), we assigned 
each of our patients to one of the three Hoshida subclasses using their transcriptional predictors. We found strong concordance be-
tween the iClusters and the Hoshida subclasses (see Table S6).
Clinical Significance of iClusters
We sought to compare the TCGA iClusters to the subtypes found by Hoshida (Hoshida et al., 2009). To accomplish this, we used gene 
the expression signatures from Hoshida et al. and used K-mean clustering to group TCGA tissues and assigned membership of tis-
sues according to subtype signature from the original study. Of 619 genes defined by Hoshida et al., expression of 610 genes were 
available in TCGA mRNA RNA-seq data. TCGA tissues were subgrouped by K-mean cluster (k = 3) and subclasses were assigned 
according to their expression patterns of subclass signature. These assignments stratified each iCluster grouping to one of 3 Hoshida 
et al. subclasses (Figure 3B).
To compare the TCGA iClusters to other published studies, we constructed a subtype prediction model using data from the TCGA
cohort. For selection of subtype-specific gene sets, multiple 2-class t tests were performed for all possible combinations of the 3 sub-
types. Gene expression differences were considered statistically significant if the p value was less than 0.001. Only genes with sig-
nificant differences in expression in all 2 possible comparisons were considered subtype-specific genes, yielding 1442 significant
genes for the iCluster1 subtype, 128 for the iCluster2 subtype, and 329 for the iCluster3 subtype. The top 200 significant genes in
iCluster1 and iCluster3 subtypes and 128 genes for the iCluster2 subtype were further selected for development of the predic-
tion model.
To develop a subtype prediction model, we adopted a previously developed model using Bayesian compound covariate predictor
algorithms. Briefly, gene expression data for each subtype gene signature (i.e., the 200 significant genes for each subtype, as
described above) were used to generate the Bayesian probability of each tissue sample belonging to a particular subtype, generating
3 probability scores for each tumor. Samples in the test cohorts were assigned to 1 of the 3 subtypes according to the highest prob-
ability scores.
When the prediction model was applied to the MDACC cohort (n = 100), the iC1 subtype was associated with the worst prognosis
and the iC2 and iC3 subtype was associated with the better prognosis (Figure 3C). Consistent with the MDACC, the iC1 subtype was
associated with worst prognosis in NCI and Fudan cohorts (see Figure 3C).
Contributors: Arshi Arora, Ronglai Shen, Ju-Seog Lee.
IDH1/2 and IDH1/2-Like Mutant Signature
IDH1/2 Mutation Signature
Four tissues (TCGA-CC-5260, TCGA-DD-A4NA, TCGA-ED-A82E, and TCGA-G3-A25T) had mutations in IDH1 or IDH2 (two muta-
tions in IDH1 (R132C, R132G) and two mutations in IDH2 (R172K, R172S)). Two-sample t test were carried out to uncover mRNAs
differentially expressed between mutant and wild-type HCC tissues and identified 1009 genes (p < 0.0001). Interestingly, several tis-
sues without IDHmutations had highly similar mRNA expression patterns (Figure 4A). When Bayesian compound covariate predictor
(BCCP) algorithm (Radmacher et al., 2002) was applied tomRNA expression data to stratify the HCC tissues according to similarity to
IDHmutation expression signature, 11 tissues without IDH1/2mutationswere classified into IDH-like subtype (Probability < 2 in range
from 0 to 4 in log2 scale).
Stratification of TCGA HCC Tissues by Known Molecular Subtypes
To assess concordance between TCGA subtypes and previously identified molecular subtypes, HCC tissues in TCGA cohort were
stratified according to molecular signatures from previous studies. Eight tumor-derived prognostic signatures were used to compar-
ison: NCI proliferation (NCIP) signature (Lee et al., 2004), hepatic stem cells (HS) signatures (Lee et al., 2006), Seoul National Univer-
sity recurrence (SNUR) signature (Woo et al., 2008), cholangiocarcinoma-like (CCL) signature (Woo et al., 2010), hepatoblastoma
16 gene (HB16) signature (Cairo et al., 2008), Hippo pathway signature (Sohn et al., 2016), Hoshida signature (Hoshida et al.,
2009), and 65-gene risk scores for recurrence (RS65) (Kim et al., 2012). Except for Hoshida signature and RS65 scores, BCCP algo-
rithm was applied to stratify TCGA tumor tissues by using previously defined gene sets and original gene expression data as training
set. For stratification according to Hoshida signature, ConsensusClusterPlus package in R (v2.13.2) (Wilkerson andHayes, 2010) was
used to group tissues into three subtypes. RS65 risk scores were was calculated by using recurrence score algorithms as described
in a previous study (Kim et al., 2012). Briefly, the risk score for each patient was derived by multiplying the expression level of a gene
with its corresponding coefficient (Risk score = sum of Cox coefficient of Gene Gi X expression value of Gene Gi). The risk scores
were rescaled 0 to 100 to make 0 as the lowest risk score. Patients were then stratified into two prognostic subtypes (high risk >
40). Significance of association between molecular subtypes with IDH1/2 signature was estimated by c2-test (Figure 4A).
IDH1/2 Mutation Signature and Clinical Significance
Wenext tested the clinical relevance of patients with IDH1/2mutant and IDH-like HCCby applying IDHmutation expression signature
to gene expression data from three independent human HCC cohorts. Gene expression data of 100 HCC tumors generated from a
University of TexasMDAnderson Cancer Center (MDACC) (Kim et al., 2012; Sohn et al., 2016) were first used for this analysis. Briefly,
a BCCP algorithm was applied to generate probability of IDH mutation signature in each of the human HCC tumors as previously
described (Lee et al., 2006; Sohn et al., 2016). When the HCC patients were dichotomized according to IDH1/2 mutation signature
probability (Figure 4B), patients with IDH1/2 mutation signature (IDH-like) had significantly worse prognosis than those without
IDH1/2 mutation signature (WT) (p = 1.0 3 104, Figure 4C), strongly indicating that IDH1/2 mutations or their activation in HCC
may dictate clinical outcome and is associated with poor prognosis. The significant association of IDH1/2 mutation signature with
worse prognosis was further validated in two independent cohorts (National Cancer Institute (NCI) cohort and Fudan University
cohort) (Figure 4C).
miR-122-5p in IDH-Like/Mut and miR-122 Gene Targets
We identified miRs that were differentially abundant between IDH-like/IDH mutant samples and IDH wild-type by nonparametric
unpaired two-class analysis (Figure S4A). Liver-specific miR-122-5p (Figure S4B), which is known to be downregulated in HCCs,
was strikingly less abundant in the IDH-like/IDH mutant group (Figure S4A). We assessed potential gene targets of this miR through
miR-mRNA anticorrelations for n = 189 samples (FDR< 0.05). The table shows the top 30 significant (FDR < 0.05) anticorrelations with
miR-122-5p that have been published as validated targets (Figure S4D). We noted that miR-122-5p was strongly anticorrelated to
PKM2, the M2 isoform of the pyruvate kinase (PK) (rho = 0.62).
Also of note is miR-885-5p with the second largest negative fold change. miR-885-5p is significantly anticorrelated with a number
of functionally validated direct targets including CCDC46 (also known as MCM5) (rho = 0.40, FDR = 1.2e-06), TP53 (rho = 0.30,
FDR = 6e-04), CDK2 (rho = 0.29, FDR = 0.001) and CTNNB1 (rho = 0.27, FDR = 0.003). Alternately, a number of miR-200 family
members (miR-200a-5p, 200b-3p and 429) were significantly more abundant in the IDH-like/IDH mutant group.
Contributors: Lisa Iype, Reanne Bowlby, Toshinori Hinoue, Jae-Jun Shim, Bo Hwa Sohn, Ju-Seog Lee.
p53 Signature
The TCGAHCC tumors with complete exome sequence data, copy number data, and expression data (n = 191) were initially stratified
by TP53mutation status. All HCC with TP53 non-synonymous missense, frameshift, nonsense, splice sites, and indels (n = 60) were
compared to HCC without TP53mutations (n = 131) for RNA expression of 20,531 analyzed genes. An unpaired t test was then per-
formed on the expression values for each gene in the two TP53 categories. t test p values for each genewere then ranked from lowest
to highest and the gene list cross-indexed with a manually curated list of 155 experimentally validated p53 transcriptional target
genes. We identified 30 known p53 target genes that were significantly upregulated (p < 0.005) in WT TP53 HCC compared to
MUT TP53 HCC. From these 30 genes we chose 20 p53 target genes that were known to be frequently upregulated in other cancer
types with WT TP53 relative to MUT TP53, as described in a previous publication(Parikh et al., 2014). These 20 genes composed the
p53 signature.
The HCC were then segregated by p53 signature. To do this, the RNA expression values for each of the 20 target genes were
ranked from 1 to 191 across the HCC samples. The expression ranks for all 20 target genes were then summed and the HCC ranked
by 20 gene score totals. For many analyses, the HCC quartile with the lowest summed scores (low p53 signature) were compared to
the quartile with the highest summed scores (high p53 signature). The ranking of the HCC by signature score and expression of each
of the p53 target genes is shown in Figure 5A. We also examined 10 p53 repressed target genes for each of the HCC and the relative
expression levels of these 10 genes are also shown in Figure 5a.
For the log-rank survival analyses in Figure S5we utilized the available follow-up survival data on the TCGAHCC dataset and strat-
ified the HCC by high and low p53 signature quartiles and an intermediate quartile composed of the second and third ranked p53
signature quartiles. The same analysis was performed in three external cohorts: a 242 HCC patient cohort from Fudan, China; a
100 HCC patient cohort from M.D. Anderson Cancer Center; a 113 HCC patient cohort from the National Cancer Institute.
To examine the association of p53 signature status and molecular/clinical correlates we performed unpaired t tests comparing the
high and low p53 signature quartile values that had parametersmeasured by continuous variables (e.g., recurrence risk score, MDM4
expression, MDM4 copy number). For discrete variables we used a chi-square test to compare the values in the high and low p53
signature quartiles (e.g., ploidy, HBV status, tumor grade). p values are shown for individual clinical and molecular parameters at
the top of Figure 5A.
Contributor: Lawrence A. Donehower.
Pathway-Associated High Impact Gene Mutations
For all mutations in the HCC cohort, the Evolutionary Action (EA) method1 was applied to predict the functional impact of missense
mutations. Nonsense mutations received a heuristic score of maximal EA impact. To identify individual genes with a strong EAmuta-
tional bias, we compared the distribution of each gene’s EA scores to that of the cancer as a whole using a one-sided two-sample
Kolmogorov Smirnov test. Genes with an FDR-corrected q-value < 0.05 were deemed significant single-gene results.
We used the Reactome pathway database (v49) to define groups of functionally related genes. Reactome is hosted by the Euro-
pean Bioinformatics Institute, encompasses 7,498 genes across 1580 pathways, and represents high-quality, manually curated
pathway information. Using all mutated genes that were not significant in single-gene analysis, we identified for each Reactome
pathway the set of genes that maximized bias toward high EAmutations using leave-one-out analysis. Sets that exhibited significant
bias (q < 0.05) after FDR correction andwere alsomore significant than at least 95%of 1,000 size-matched pathway simulationswere
considered to be of interest. Sets of interest were then ranked by their fold improvement over the threshold set by the simulations
(Figure S7, Table S7).
Contributors: Amanda Koire, Panagiotis Katsonis, Teng-Kuei Hsu, Olivier Lichtarge.
Immune Signature
The normalized RNA-seq gene expression data and the CIBORSORT cellular composition data were downloaded from TCGA Syn-
apse (Syn4976369 and Syn7337221, respectively). The unsupervised hierarchical clustering of gene expression was done using the
Next-Generation (Clustered) Heatmaps (NG-CHM, http://bioinformatics.mdanderson.org/chm).
Contributor: Linghua Wang.
Interactive Exploration
To gain greater insight into the development and progression of hepatocellular carcinoma, we have integrated all of the data types 
produced by TCGA and described in this paper into a single ‘‘feature matrix.’’ From this single heterogeneous dataset, significant 
pairwise associations have been inferred using statistical analysis and can be visually explored in a genomic context using Regulome 
Explorer, an interactive web application (http://explorer.cancerregulome.org). In addition to associations that are inferred directly
from the TCGA data, additional sources of information and tools are integrated into the visualization for more extensive exploration
(e.g., NCBI Gene, miRBase, the UCSC Genome Browser, etc).
Feature Matrix Construction
A feature matrix was constructed using all available clinical, sample, and molecular data for 196 unique patient/tumor samples. The
clinical information includes features such as age and tumor size; while the sample information includes features derived from
molecular data such as single-platform cluster assignments. The molecular data include mRNA and microRNA expression levels
(Illumina HiSeq data), protein levels (RPPA data), copy number alterations (derived from segmented Affymetrix SNP data as well
as GISTIC regions of interest and arm-level values), DNA methylation levels (Illumina Infinium Methylation 450k array), and somatic
mutations. For mRNA expression data, gene level RSEM values from RNA-seq were log2 transformed, and filtered to remove low-
variability genes (bottom 25% removed, based on interdecile range). For miRNA expression data, the summed and normalized
microRNA quantification files were log2 transformed, and filtered to remove low-variability microRNAs (bottom 25% removed, based
on interdecile range). For methylation data, probes were filtered to remove the bottom 25% based on interdecile range. For somatic
mutations, several binary mutation features indicating the presence or absence of a mutation in each sample were generated.
Mutation types considered were synonymous, missense, nonsense, and frameshift. Protein domains (InterPro) including any of these
mutation types were annotated as such, with nonsense and frameshift annotations being propagated to all subsequent protein
domains.
Pairwise Statistical Significance
Statistical association among the diverse data types in this study was evaluated by comparing pairs of features in the feature matrix.
Hypothesis testing was performed by testing against null models for absence of association, yielding a p value. p values for the as-
sociation between and among clinical and molecular data types were computed according to the nature of the data levels for each
pair: categorical versus categorical (Chi-square test or Fisher’s exact test in the case of a 2x2 table); categorical versus continuous
(Kruskal-Wallis test) or continuous versus continuous (probability of a given Spearman correlation value). Ranked data values were
used in each case. To account for multiple-testing bias, the p value was adjusted using the Bonferroni correction.
Exploring Significant Feature Associations
Regulome Explorer allows the user to interactively explore significant associations between various types of features – associations
between molecular features (like methylation and gene expression), associations between molecular features and derived numeric
features (like RS65 Score), and associations betweenmolecular features and categorical features such as clinical features or clusters
derived from prior analysis (like iCluster).
Contributors: Lisa Iype, Sheila M. Reynolds.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification methods and statistical analysis methods for each of the various data platforms and for integrated analyses are
described and referenced in their respective Method Details subsections.
DATA AND SOFTWARE AVAILABILITY
The raw data for TCGA LIHC individual platforms, including DNA exome sequence, RNA expression sequence, miRNA expression
sequence, DNA methylation beta values, SNP Array (copy number data), and RPPA proteomics data) are archived and publicly
available in the Genomic Data Commons (https://gdc.cancer.gov/). Clinical data, and analysis results from other data platforms
are in Synapse found at https://www.synapse.org/#!Synapse:syn2318326/files/. Data access requires authorization through dbGaP
obtained by visting https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login.
Software used for the analyses for each of the data platforms and integrated analyses are described and referenced in the indi-
vidual Method Details subsections and listed in the Key Resources Table.
Supplemental Figures
Figure S1. TERT Alterations and Exomic Mutational Signatures in HCC, Related to Figure 1
(A) TERT promoter mutations, gene amplification, and fusion RNAs likely to result in increased TERT RNA expression occur in over 50% of the core 196 HCC
dataset. These are indicated in the top bar. The second and third bars indicate that CDKN2A RNA expression is frequently reduced by both promoter
hypermethylation (second bar) and deep deletion (third bar). Chi-square analysis showed that CDKN2A silencing is highly correlated with TERT alterations
(p = 8.1 X 105).
(B) Hierarchical clustering of normalized signature activity in the core 196 HCC dataset. Hierarchical clustering of the normalized signature activity in TCGA HCC
identified the aristolochic acid (AA) cluster of 9 cases with the enriched Sig.A activity (COSMIC 22) and the aflatoxin B1 (AFB1) cluster of 25 cases affected by the
Sig.B (COSMIC 24) activity. Six out of top seven samples with the highest Sig.B activity in the AFB1 cluster were overlapping with the AFB1-affected samples
identified by the independent mutation signature analysis (Schulze et al., 2015, Nature Genet. 47:505-511).
(C) Boxplot of AFB1-signature associatedmutations in TP53-R249S (known AFB1 hotspot site) mutant samples, other TP53mutant samples, and TP53wild-type
samples reveals a significant enrichment of AFB1 activity in samples harboring TP53-R249S mutations (p = 0.0052 versus other TP53 mutant group and 0.00011
versus TP53 wild-type group, Wilcoxon rank-sum test).
Bold midlines for each category are median values. Lighter lines indicate upper (75%) and lower (25%) quartiles.
Figure S2. HCC Copy Number Alterations and their Molecular and Clinical Correlates, Related to Figure 1
(A) In the heatmap at the right part of the panel, copy number losses or gains (see legend at right) in individual tumors (vertical axis) are plotted by chromosomal
location (horizontal axis). Tumors were hierarchically clustered by significantly reoccurring copy number alterations identified by GISTIC 2.0 analysis of the entire
dataset. Vertical sidebars (left) show the cluster designations, patient information, gene mutations, and other clinical and molecular correlates.
(B) GISTIC 2.0 amplifications and deletions across all HCC. Chromosomal locations of peaks of significantly recurring focal amplifications (red) and deletions
(blue) are plotted by FDRs. Annotated peaks have an FDR < 0.2 and encompass 50 or fewer genes. Peaks are annotated with candidate driver oncogenes, tumor
suppressors, fragile site genes (green) or by cytoband. The number of genes within each peak is shown next to driver genes or cytobands.
Figure S3. iCluster Correlation with Molecular, Demographic, and Clinical Features of HCC, Related to Figure 3
(A) Prediction signatures for iCluster subtypes of HCC in the TCGA dataset. iCluster subtype-specific gene expression signatures were identified by applying
multiple t tests (p < 0.001). Among the significant genes in each subtype, the top 200 genes were selected for development of predictionmodels (all 128 significant
genes were used for the iC2 subtype). Data are presented in matrix format in which each row represents an individual gene and each column represents a tumor
sample. Each cell in the matrix represents the expression level of a gene feature in an individual tissue sample. The coloring in the cells reflects relatively high (red)
and low (green) expression levels, as indicated in the scale bar (log2 transformed scale). The three transcription-based prediction models were used to classify
patients from published studies.
(B) Correlation of iCluster groupings of patients with demographic and clinical categories.
(C) Each patient was assigned to a molecular cluster category from the indicated individual platform. Colored tiles indicate the cluster membership of the patient
within a given molecular platform. To the right are shown p values for the distribution of each platform cluster within the iCluster groupings.
(D) Differential expression of selected miRNAs and genes by iCluster analysis.
Midlines in each box plot represent median values for each category. Box edges define the population quartiles (25% and 75%). Whiskers above the boxes
represent maximum values or quartile 3 values plus 1.5 times the quartile 3 minus quartile 1 values, whichever is smaller. Whiskers below the boxes represent
minimum values or quartile 1 values minus 1.5 times the quartile 3 minus the quartile 1 values, whichever is larger.
Figure S4. miR-122-5p, IDH-Like/Mut versus Wild-Type and miR-122 Gene Targeting, Related to Figure 4
(A) The top 15 significantly up and downregulatedmiRNAs in IDH-like/IDHmutant samples relative to IDHwild-type samples. For eachmiRNA, the bar plot shows
the fold change between the medians and the boxplot shows the log10 abundance between the two groups.
(B) miR-122-5p abundance in tumor and normal samples from a range of TCGA tissue types.
(C) Scatterplot correlating miRNA-122 expression with hypermethylation of its promoter (representative CpG site cg00481280). Note a fraction of HCC (bottom
right) with high methylation and low expression (red dots indicate the five most hypermethylated tumors).
(D) The top 30 significant (FDR < 0.05) miRNA-mRNA anti-correlations that have been functionally validated as direct targets of miR-122-5p.
Midlines in each box represent median values, while box edges represent 25% and 75% quartile values.
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Figure S5. HCC with Low p53 Target Expression Signatures Display Poorer Prognosis, Related to Figure 5
(A) TCGA HCC (192 patients) in the lowest quartile of p53 target gene expression were compared for overall survival to those in the highest quartile of p53 target
gene expression by log-rank survival analyses.
(B) An external cohort of 242 HCC patients from Fudan, China were compared for survival of patients with high versus low p53 signatures as described for panel a.
(C) A 100 HCC patient cohort from M.D. Anderson Cancer Center was compared by p53 low and high signature quartiles for overall survival.
(D) A 113 HCC patient cohort from the National Cancer Institute was compared by p53 low and high signature quartiles for overall survival.
AB
Figure S6. Stratification of HCC Pathways and Gene Alterations by iCluster Categories, Related to Figure 6
(A) Pathway stratification by iCluster categories. Shown are percentages of samples in each subgroup that have at least one alteration in any of the genes
associated to each pathway (as shown in Figure 6). Cells are shaded green in proportion to their percentage of alteration.
(B) Driver gene stratification by iCluster categories. The oncoprint summarizes co-occurrence and mutual exclusivity of some of the most relevant somatic al-
terations across samples and iClusters. ‘‘Deep deletions’’ correspond to cases where more than half of the copies of a gene are deleted from the baseline ploidy.
Missensemutations are only included if they have known oncogenic function, have previously been reported in COSMIC, or occur at knownmutational hotspots.
Figure S7. Enrichment of Functionally Important Gene Mutations within Specific HCC Signaling Pathways, Related to Figure 6
Mutation Action Profiles (MAPs) in HCC.
(A) Mutation Action Profiles (MAPs) of two representative genes not under positive selection. Nonsynonymous mutations are binned in deciles by their Action
score, with higher scores indicating a larger functional impact. Absolute counts of mutations in each bin are represented by the height of the bin.
(B) MAPs of TP53 and CTNNB1, two individual genes under strong positive selection.
(C–H) MAPs of selected gene sets under positive selection collectively. Each component gene is represented by a color and plots are labeled with the Reactome
pathway associated with the gene set.
